Original Article
A Comparison of Sustained-Release Bupropion and Placebo for Smoking Cessation
N Engl J Med 1997; 337:1195-1202October 23, 1997
- Abstract
Background and Methods
Trials of antidepressant medications for smoking cessation have had mixed results. We conducted a double-blind, placebo-controlled trial of a sustained-release form of bupropion for smoking cessation. We excluded smokers with current depression, but not those with a history of major depression. The 615 subjects were randomly assigned to receive placebo or bupropion at a dose of 100, 150, or 300 mg per day for seven weeks. The target quitting date (or “target quit date”) was one week after the beginning of treatment. Brief counseling was provided at base line, weekly during treatment, and at 8, 12, 26, and 52 weeks. Self-reported abstinence was confirmed by a carbon monoxide concentration in expired air of 10 ppm or less.
Results
At the end of seven weeks of treatment, the rates of smoking cessation as confirmed by carbon monoxide measurements were 19.0 percent in the placebo group, 28.8 percent in the 100-mg group, 38.6 percent in the 150-mg group, and 44.2 percent in the 300-mg group (P<0.001). At one year the respective rates were 12.4 percent, 19.6 percent, 22.9 percent, and 23.1 percent. The rates for the 150-mg group (P = 0.02) and the 300-mg group (P = 0.01) — but not the 100-mg group (P = 0.09) — were significantly better than those for the placebo group. Among the subjects who were continuously abstinent through the end of treatment, the mean absolute weight gain was inversely associated with the dose (a gain of 2.9 kg in the placebo group, 2.3 kg in 100-mg and 150-mg groups, and 1.5 kg in the 300-mg group; P = 0.02). No effects of treatment were observed on depression scores as measured serially by the Beck Depression Inventory. Thirty-seven subjects stopped treatment prematurely because of adverse events; the frequency was similar among all groups.
Conclusions
A sustained-release form of bupropion was effective for smoking cessation and was accompanied by reduced weight gain and minimal side effects. Many participants in all groups were smoking at one year.
Media in This Article
Figure 3
Mean Change from Base Line in the Withdrawal Score.Figure 1
Rates of Confirmed Continuous Abstinence from the Target Quitting Date through the End of Treatment.Article Activity
- Article
Pharmacologic treatments such as nicotine-replacement therapy have been shown to help smokers stop smoking. Using a medication that does not contain nicotine, such as an antidepressant, has intrigued investigators for several reasons. Smokers are more likely to have a history of major depression than nonsmokers,1,2 and nicotine may act as an antidepressant in some smokers.3,4 The development of a depressed affect or depression after smoking cessation may lead to relapse.5-7
Results of clinical trials of antidepressant therapy for smoking cessation have been mixed. The initial experience with doxepin was promising; however, no large trials have been reported.8 The results of trials of fluoxetine have not been published. A serotonin-uptake inhibitor had no effect on smoking rates in heavy smokers.9 An immediate-release form of bupropion (300 mg per day for 12 weeks) showed efficacy in two double-blind, placebo-controlled trials, one with 42 male smokers and the other with 190 smokers.10 On the basis of these results, we evaluated the efficacy and safety of a sustained-release form of bupropion (Zyban, Glaxo Wellcome) as an aid to smoking cessation. This form of bupropion was recently approved by the Food and Drug Administration as a prescription drug for the indication of smoking cessation.
Methods
Subjects
This randomized, double-blind, placebo-controlled, dose–response study was performed at three sites (Mayo Clinic, Rochester, Minn.; the Palo Alto Center for Pulmonary Disease Prevention, Palo Alto, Calif.; and West Virginia University, Morgantown) and approved by each center's institutional review board. Recruitment was conducted through advertisements and press releases. A total of 742 volunteers who were interested in stopping smoking were evaluated, of whom 615 met the study criteria and underwent randomization. After an initial screening interview conducted by telephone, subjects attended an informational meeting at which the study was explained, questionnaires completed, and written informed consent provided.
The subjects were eligible for inclusion if they were at least 18 years of age, had smoked an average of 15 cigarettes or more per day for the past year, were motivated to stop smoking, and were in generally good health. Only one smoker per household was allowed in the study. Exclusion criteria included the presence or a family history of a seizure disorder, a history of severe head trauma, predisposition to seizures (such as a history of brain tumor or stroke), a history or current diagnosis of anorexia nervosa or bulimia, the presence of an unstable medical or psychiatric condition, pregnancy, lactation, a history of dependence on alcohol or a non-nicotine substance within the past year, current use of psychotropic medications, previous use of bupropion, current use of tobacco products other than cigarettes, and current use of any nicotine-replacement therapy, fluoxetine, clonidine, buspirone, or doxepin. Subjects with current depression as assessed by the physician were also excluded. Those with a history of major depression as assessed by a structured clinical interview were not excluded.11
At the base-line visit subjects were randomly assigned to receive either a sustained-release form of bupropion at a dose of 100 mg per day (50 mg twice a day), 150 mg per day (150 mg each morning and placebo each evening), or 300 mg per day (150 mg per day for three days, followed by 150 mg twice a day) or placebo (twice a day). All the tablets were identical in appearance. Subjects set a target quitting date (or “target quit date”) after one week of medication (usually the eighth day). They returned weekly during the 7-week treatment phase, then at 8, 12, 26, and 52 weeks for follow-up. The subjects were telephoned 3 days after the target quitting date and at 4, 5, 7, 8, 9, 10, and 11 months. At the base-line physical examination, each subject received a brief, personalized message to stop smoking from the physician and self-help material based on the National Cancer Institute program.12 In this program, which has been validated as an effective intervention for smoking cessation, the physician asks each patient whether he or she smokes, advises all smokers to stop smoking, helps the patient set a quitting date, and arranges a follow-up visit.
Subjects underwent chest roentgenography, laboratory testing, electrocardiography, and physical examination. We obtained data on smoking history, asked subjects to keep a daily diary to record smoking rates and symptoms of nicotine withdrawal,13 and administered several questionnaires.14-16 The eight-item Fagerström Tolerance Questionnaire is a widely used measure of nicotine dependence with a score ranging from 0 to 11; a score of 6 or greater indicates higher levels of dependence.17 The Beck Depression Inventory is a 21-item questionnaire completed by the subject that assesses the severity of depressive symptoms.15 Total scores range from 0 to 63, with scores of 9 or below considered to be within the normal range. Scores of 10 to 18 indicate mild-to-moderate depression, scores of 19 to 29 indicate moderate-to-severe depression, and scores of 30 or higher indicate severe depression. Each week we collected the subjects' daily diaries and recorded concomitant medication use, adverse events, vital signs, and the carbon monoxide content of expired air. Self-reported abstinence was considered validated by a carbon monoxide level in expired air of 10 ppm or below. Brief individual counseling (approximately 10 to 15 minutes) was provided by a study assistant at each visit.
Statistical Analysis
The sample size was based on the ability to detect a difference between active treatment and placebo at the end of treatment, given a projected abstinence rate of 40 percent in the bupropion groups and 24 percent in the placebo group. Approximately 130 subjects were needed for each treatment group, in order to have a two-sided alpha level of 0.05 and a power of 0.80 to detect such a difference. To ensure an adequate sample, 150 subjects were enrolled in each treatment group.
The base-line characteristics of the four groups of subjects were compared by analysis of variance for continuous variables and chi-square analysis for categorical variables. The efficacy of smoking cessation was evaluated with the use of weekly point-prevalence abstinence rates and rates of continuous abstinence. For the point-prevalence rates, subjects were classified as abstinent if they reported not smoking during the previous seven days and this report was confirmed by an expired carbon monoxide value of 10 ppm or less. To be classified as continuously abstinent, the subjects had to be confirmed as not smoking on the basis of carbon monoxide measurement at each visit. In all cases, an intention-to-treat analysis was performed. Subjects who missed a follow-up visit were considered to be smoking. Randomization of subjects was stratified according to site to ensure that similar numbers of subjects were assigned to each group at each site. However, to verify the assumption that the effect of treatment was not dependent on the study site, the efficacy of smoking cessation was first evaluated with logistic-regression modeling. In these models, the dependent variable was smoking status, as confirmed by carbon monoxide measurement, and the independent variables were dose (placebo vs. 100 mg vs. 150 mg vs. 300 mg of bupropion) and study site (California vs. Minnesota vs. West Virginia). We included an interaction term to assess whether the effect of dose was dependent on the study site. After verifying that the effect of treatment was not dependent on the study site, we performed a logistic-regression analysis to assess differences between groups including site as a covariate. The comparisons of placebo with 100 mg of bupropion, placebo with 150 mg of bupropion, and placebo with 300 mg of bupropion were identified a priori to be of specific interest.
Body weight was analyzed among subjects who were continuously abstinent during the treatment phase. The absolute change in weight from base line was calculated weekly from the start of medication through the end of treatment. The effect of dose was evaluated with a two-factor repeated-measures analysis of variance model, with dose as an independent continuous cross-classification factor and time as the repeated factor. We included an interaction term to assess whether the effect of dose was consistent over time. Linear regression and pairwise dose comparisons were used to supplement these analyses.
Withdrawal symptoms were assessed daily with a composite withdrawal score computed as the mean of the nine items included in the daily diary. Symptoms of nicotine withdrawal included craving for a cigarette; depressed mood; difficulty falling asleep; awakening at night; irritability, frustration, or anger; anxiety; difficulty concentrating; restlessness; and increased appetite. The severity of each symptom was scored by the subject on a five-point scale as absent (0), slight (1), mild (2), moderate (3), or severe (4). For each subject a base-line withdrawal score was calculated with data from all diaries completed before the start of medication, during which time the subjects were instructed to continue smoking their usual number of cigarettes. Withdrawal-symptom scores obtained after the target quitting date were analyzed as the change from base line. The data were summarized daily for the first week after the target quitting date and as weekly means for each of the next five weeks. For each group, the mean change in the withdrawal score was compared with zero by the one-sample t-test. The effect of treatment was evaluated with a two-factor repeated-measures analysis of variance model in which change in the withdrawal score was the dependent variable, treatment group was an independent cross-classification factor, and time was the repeated factor. Separate analyses were performed for the daily summary of week 1 and the weekly summary of the entire treatment phase. In addition to the overall model, separate pairwise analyses were performed that compared each active-treatment group with placebo.
Symptoms of depression were assessed with the Beck Depression Inventory15 at base line and at weeks 2 and 6 after the target quitting date. Depression scores were analyzed in terms of the change from base line. For each group, the mean change in the depression score was compared with zero by the one-sample t-test. The effect of treatment was evaluated with a two-factor repeated-measures analysis of variance model in which change in the depression score was the dependent variable, treatment group was an independent cross-classification factor, and time was the repeated factor. Fisher's exact test was used to compare the rates of adverse events for each active-treatment group with those in the placebo group.
Results
The base-line characteristics of the subjects are presented in Table 1Table 1
Base-Line Characteristics of the Subjects.. There were no significant differences among the groups. A total of 219 subjects (148 during the treatment phase and 71 subsequently) did not complete the 12-month study. Of these subjects, 196 (89 percent) withdrew their consent for various reasons (e.g., scheduling difficulties or perceived lack of benefit); 15 stopped participating because of an adverse event, 6 because of protocol deviations, and 1 for administrative reasons; 1 subject died. The rate of completion of the study increased with the dose and was 57 percent, 65 percent, 64 percent, and 71 percent for the placebo, 100-mg, 150-mg, and 300-mg groups, respectively (P = 0.01 by logistic-regression analysis in which dose was treated as a continuous variable).The biochemically confirmed point-prevalence smoking-cessation rates according to treatment are shown in Table 2Table 2
Point-Prevalence Smoking-Cessation Rates Confirmed by Carbon Monoxide Measurement.. At the end of the treatment phase (week 6 after the target quitting date), the cessation rate for each of the three active-treatment groups was significantly better than for the placebo group. Subjects who received 300 mg of bupropion per day had a significantly better (P = 0.005) cessation rate than those who received 100 mg per day. The respective point-prevalence smoking-cessation rates at six weeks and one year were 19.0 percent and 12.4 percent in the placebo group and 44.2 percent and 23.1 percent in the group that received 300 mg of bupropion. At one year, the smoking-cessation rates for the 150-mg and 300-mg groups — but not the 100-mg group — were significantly better than that for the placebo group. When dose was treated as a continuous variable, a significant dose effect was detected at all periods (P<0.001 at week 6, P = 0.003 at 3 months, P = 0.03 at 6 months, and P = 0.02 at 12 months).Figure 1Figure 1
Rates of Confirmed Continuous Abstinence from the Target Quitting Date through the End of Treatment. shows the rates of continuous abstinence from the target quitting date through the end of treatment (10.5 percent in the placebo group, 13.7 percent in the 100-mg group, 18.3 percent in the 150-mg group, and 24.4 percent in the 300-mg group). The rate of continuous abstinence was significantly better in the group that received 300 mg of bupropion than in the placebo group (P = 0.001) and in the group that received 100 mg of bupropion (P = 0.02).Weight Change
The mean change in weight from the start of medication (base line) for the 103 subjects who were continuously abstinent during the treatment phase is shown in Figure 2Figure 2
Mean Change in Weight from Base Line through the End of Treatment among 103 Subjects Who Were Continuously Abstinent.. At the end of treatment, the subjects had gained a mean of 2.9 kg in the placebo group (16 subjects), 2.3 kg in the 100-mg group (21 subjects) and the 150-mg group (28 subjects), and 1.5 kg in the 300-mg group (38 subjects). Weight change was negatively associated with the dose (P = 0.003, by repeated-measures analysis of variance), with evidence of an interaction between dose and time (P = 0.04) that indicated a larger disparity between doses at later periods. For each of the first six weeks after the target quitting date, weight change was negatively associated with dose, with less weight gain found with higher doses of bupropion. Of the 59 subjects who were continuously abstinent from the target quitting date to the six-month follow-up visit, the mean weight gain was not significantly associated with dose: 5.5 kg in the placebo group (9 subjects), 6.6 kg in the 100-mg group (10 subjects), 4.4 kg in the 150-mg group (21 subjects), and 4.5 kg in the 300-mg group (19 subjects).Symptoms of Depression and Withdrawal
During the medication phase, there was no evidence of a difference in change among treatment groups in the mean scores on the Beck Depression Inventory. In addition, the change in scores from base line was not significantly different from zero for any group either two weeks after the target quitting date (mean ±SD change, -0.3±4.7 in the placebo group [121 subjects], +0.4±4.1 in the 100-mg group [124 subjects], +0.6±4.9 in the 150-mg group [123 subjects], and +0.3±5.0 in the 300-mg group [128 subjects]) or at the end of treatment (-0.8±4.7 [103 subjects]; +0.5±5.5 [115 subjects]; -0.4±5.7 [110 subjects], and +0.8±5.2 [128 subjects], respectively).
The mean changes from base line in the composite withdrawal scores are shown in Figure 3Figure 3
Mean Change from Base Line in the Withdrawal Score.. For each group, the mean change from base line was significantly greater than zero (i.e., withdrawal symptoms increased) at all periods. For the first week after the target quitting date, the change in the withdrawal scores was not significantly different among the four treatment groups. In the analysis of the weekly means, a significant treatment effect was detected (P<0.001). From the pairwise comparisons of the active-treatment groups with the placebo group, only the 100-mg group had significantly more withdrawal symptoms (P = 0.008) than the placebo group. There were no significant interactions between time and treatment.Despite explicit instructions to the contrary, seven subjects used nicotine-replacement products during the study, only one of whom stopped smoking at any point. That subject chewed one piece of nicotine gum on day 17 before remembering he was not to do so.
Safety
All adverse events reported one or more times by at least 10 percent of subjects in any given treatment group are shown in Table 3Table 3
Adverse Events among Subjects.. A total of 37 subjects stopped treatment prematurely because of adverse events (8 in the placebo group [5 percent], 9 in the 100-mg group [6 percent], 7 in the 150-mg group [5 percent], and 13 in the 300-mg group [8 percent]). Tremor, headaches, rash, and urticaria were the most common reasons for stopping treatment.Three serious adverse events were reported during or immediately after the medication phase. A 23-year-old man assigned to receive 300 mg of bupropion per day reported extreme irritability, restlessness, anger, anxiety, and cravings soon after he stopped smoking. The study medication was stopped, and he began treatment with a nicotine patch. Two days later he was doing well. A 66-year-old woman assigned to the 300-mg group had an allergic reaction manifested by a pruritic rash, angioedema, dyspnea, and petechiae. She had received bupropion for 24 days, but had begun taking amoxicillin–clavulanate for the treatment of bronchitis 8 days before the onset of the reaction. The bupropion and amoxicillin–clavulanate were stopped, and the reaction resolved after treatment with antihistamines, epinephrine, and corticosteroids. The reaction was judged to be most likely related to amoxicillin–clavulanate. A 63-year-old woman with preexisting cardiomyopathy and hypertension had cardiac and pulmonary arrest four days after completing the treatment phase (300-mg group) and died nine days later.
Discussion
We found that the sustained-release form of bupropion was an effective treatment for smoking cessation, although many participants in all groups were smoking at one year. There was a significant dose response at all periods. Furthermore, the rates of abstinence at one year were significantly better in the 150-mg group (P = 0.02) and the 300-mg group (P = 0.01) than in the placebo group. Although the 300-mg dose was the most effective initially, its effects were not significantly different from those of the 150-mg dose at the end of treatment or at one year. Nonetheless, the 300-mg dose was the only one to show a difference in the rates of continuous abstinence from the target quitting date through the end of treatment. Thus, we would recommend using the 300-mg dose (150 mg twice a day) as the target dose for most patients, given the favorable side-effect profile and the fact that there was less weight gain during the medication phase with this dose. Because steady-state plasma levels of bupropion are usually reached within eight days, we started the medication at least seven days before the target quitting date in order to ensure that these levels were attained.18 We used bupropion for seven weeks on the basis of pilot studies and experience with nicotine-patch therapy, which showed that extending treatment beyond eight weeks does not appear to increase efficacy.19 Although this duration of therapy may be adequate, a longer duration may be appropriate if relapse is a concern. Antidepressants are commonly used for several months to treat depression or chronic pain and have little potential for abuse. We did not, however, study a longer duration of treatment.
Another important finding was the significantly smaller weight gain in subjects who continuously abstained from smoking and who were receiving higher doses of bupropion. The typical weight gain associated with successful smoking cessation is 3 to 4 kg,20 and it is a concern that inhibits many smokers (especially women) from attempting to stop.21 Nicotine-replacement therapy has had mixed results in controlling weight gain after smoking cessation,22-27 with nicotine gum and nicotine nasal spray showing the greatest benefit. A medication effective for smoking cessation that is also capable of minimizing the associated weight gain would offer a major advantage.28 Bupropion seems to have that potential, even though the differences observed were moderate, and the effect seems to be limited to the time the drug is used. The effect of a longer treatment period on weight gain has not been determined.
Nicotine activates central nervous system pathways to release norepinephrine, dopamine, and other neurotransmitters29,30 and elevates dopamine levels in areas of the brain associated with the reinforcement of the effects of amphetamines, cocaine, and opiates.31-33 Bupropion is a weak inhibitor of the neuronal uptake of norepinephrine and dopamine but has no effect on serotonin.34 Its dopaminergic and noradrenergic activities could be responsible for its efficacy in smoking cessation, with the dopaminergic activity affecting areas of the brain having to do with the reinforcement properties of addictive drugs and the noradrenergic activity affecting nicotine withdrawal.34 We observed no treatment effects on depression scores as measured serially by the Beck Depression Inventory; thus, the mechanism for bupropion's efficacy is unlikely to be through its antidepressant effects. However, subjects with current depression were excluded from this study. Further study is needed for a full understanding of the responsible mechanisms.
Bupropion was well tolerated, with the most frequent adverse effects being headache, insomnia, and dry mouth. Antidepressants are associated with a small risk of seizure.35 For sustained-release bupropion used for the treatment of depression, this risk is 0.1 percent for doses of up to 300 mg per day (i.e., one seizure per 1000 subjects receiving bupropion for varying periods of time — from a few weeks to more than a year).36 Our study lacked adequate power to evaluate seizures at these low rates. None of the 462 subjects in this study who received bupropion had a seizure. However, we excluded potential subjects who had a personal or family history of seizures, a history of severe head trauma, eating disorders, or active alcoholism. In clinical practice, patients should be screened for the possibility of seizure before they start treatment with bupropion.
Even though relief of nicotine-withdrawal symptoms is not a prerequisite for smoking cessation, we were puzzled by the finding that subjects who received 100 mg of bupropion a day had a higher mean score for withdrawal symptoms. A possible explanation is that a dose of 50 mg twice a day was sufficient to produce side effects that could be interpreted as similar to withdrawal symptoms, but was not sufficient to reduce the severity of true withdrawal symptoms.
The strengths of our study are the sample size, the use of multiple centers, the dose response, and the efficacy demonstrated by point-prevalence rates and rates of continuous abstinence. However, subjects who enroll in clinical trials are motivated to stop smoking and may not be representative of the general population of smokers. Much remains to be learned, such as the optimal duration of treatment, the potential role of combination therapy with nicotine-replacement products, and the use of bupropion for smoking cessation in smokers with depression.
Supported by a grant from Glaxo Wellcome.
We are indebted to the following people for their hard work and assistance in completing this project: Marilyn Eischen, Karen Hurtis, and Troy Wolter from the Mayo Clinic; Paul M. Maloney, Lynne D. Rowe, R.N., Alicia B. Gonzales, Susan L. Winget, Carol A. Sontag, R.N., and Barbara Newman from the Palo Alto Center for Pulmonary Disease Prevention; and Connie Cerullo and Anna Greco from the West Virginia University Health Sciences Center.
Source Information
From the Nicotine Research Center (R.D.H., L.C.D., I.T.C.), the Section of Biostatistics (K.P.O., D.R.S.), and the Division of Community Internal Medicine (R.D.H., L.C.D.), Mayo Clinic and Mayo Foundation, Rochester, Minn.; the Palo Alto Center for Pulmonary Disease Prevention, Palo Alto, Calif. (D.P.L.S.); Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown (E.D.G., P.N.G., C.R.S., P.M.S.); and Glaxo Wellcome, Inc., Research Triangle Park, N.C. (J.A.J., M.A.K.).
Address reprint requests to Dr. Hurt at the Mayo Clinic, 200 First St. SW, Rochester, MN 55905.
- References
References
1
Glassman AH ,Helzer JE ,Covey LS , et al. Smoking, smoking cessation, and major depression. JAMA 1990;264:1546-1549
CrossRef | Web of Science | Medline2
Hall SM ,Munoz R ,Reus V . Smoking cessation, depression and dysphoria. NIDA Res Monogr 1991;105:312-3133
Glass RM . Blue mood, blackened lungs: depression and smoking. JAMA 1990;264:1583-1584
CrossRef | Web of Science | Medline4
Hughes JR. Dependence potential and abuse liability of nicotine replacement therapies. In: Pomerleau O, Pomerleau C, eds. Progress in clinical evaluation. New York: Alan R. Liss, 1988:261-77.
5
Covey LS ,Glassman AH ,Stetner F . Depression and depressive symptoms in smoking cessation. Compr Psychiatry 1990;31:350-354
CrossRef | Web of Science | Medline6
Hall SM ,Munoz RF ,Reus VI . Cognitive-behavioral intervention increases abstinence rates for depressive-history smokers. J Consult Clin Psychol 1994;62:141-146
CrossRef | Web of Science | Medline7
Shiffman S . Relapse following smoking cessation: a situational analysis. J Consult Clin Psychol 1982;50:71-86
CrossRef | Web of Science | Medline8
Edwards NB ,Murphy JK ,Downs AD ,Ackerman BJ ,Rosenthal TL . Doxepin as an adjunct to smoking cessation: a double-blind pilot study. Am J Psychiatry 1989;146:373-376
Web of Science | Medline9
Sellers EM ,Naranjo C ,Kadlec K . Do serotonin uptake inhibitors decrease smoking? Observations in a group of heavy drinkers. J Clin Psychopharmacol 1987;7:417-420
CrossRef | Web of Science | Medline10
Ferry LH ,Burchette RJ . Efficacy of bupropion for smoking cessation in non-depressed smokers. J Addict Dis 1994;13:249-249
Web of Science11
Spitzer RL, Williams JBW, Gibbon M, First MB. User's guide for the structured clinical interview for DSM-III-R: SCID. Washington, D.C.: American Psychiatric Press, 1990.
12
Glynn TJ, Manley MW. How to help your patients stop smoking: a National Cancer Institute manual for physicians. Bethesda, Md.: National Cancer Institute, 1990. (NIH publication no. 90-3064.)
13
Hughes JR ,Hatsukami D . Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 1986;43:289-294
CrossRef | Web of Science | Medline14
Fagerstrom KO . Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav 1978;3:235-241
CrossRef | Web of Science | Medline15
Beck AT, Steer RA. Beck Depression Inventory. Philadelphia: Center for Cognitive Therapy, 1978.
16
Swenson WM ,Morse RM . The use of a self-administered alcoholism screening test (SAAST) in a medical center. Mayo Clin Proc 1975;50:204-208
Web of Science | Medline17
Fagerstrom KO ,Schneider NG . Measuring nicotine dependence: a review of the Fagerström Tolerance Questionnaire. J Behav Med 1989;12:159-182
CrossRef | Web of Science | Medline18
Ferris RM ,Cooper BR . Mechanism of antidepressant activity of bupropion. J Clin Psychiatry Monogr 1993;11:2-1419
Fiore MC ,Smith SS ,Jorenby DE ,Baker TB . The effectiveness of the nicotine patch for smoking cessation: a meta-analysis. JAMA 1994;271:1940-1947
CrossRef | Web of Science | Medline20
Williamson DF ,Madans J ,Anda RF ,Kleinman JC ,Giovino GA ,Byers T . Smoking cessation and severity of weight gain in a national cohort. N Engl J Med 1991;324:739-745
Full Text | Web of Science | Medline21
Klesges RC ,Somes GW ,Pascale R , et al. Knowledge and beliefsregarding the consequences of cigarette smoking and their relationshipsto smoking status in a biracial sample. Health Psychol 1988;7:387-401
CrossRef | Web of Science | Medline22
Tonnesen P ,Fryd V ,Hansen M , et al. Effect of nicotine chewing gum in combination with group counseling on the cessation of smoking. N Engl J Med 1988;318:15-18
Full Text | Web of Science | Medline23
Nides M ,Rand C ,Dolce J , et al. Weight gain as a function of smoking cessation and 2-mg nicotine gum use among middle-aged smokers with mild lung impairment in the first 2 years of the Lung Health Study. Health Psychol 1994;13:354-361
CrossRef | Web of Science | Medline24
Leischow SJ ,Sachs DPL ,Bostrom AG ,Hansen MD . Effects of differing nicotine-replacement doses on weight gain after smoking cessation. Arch Fam Med 1992;1:233-237
CrossRef | Medline25
Transdermal Nicotine Study Group
CrossRef | Web of Science26
Sachs DPL ,Sawe U ,Leischow SJ . Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling. Arch Intern Med 1993;153:1881-1890[Erratum, Arch Intern Med 1993;153:2321.]
CrossRef | Web of Science | Medline27
Sutherland G ,Stapleton JA ,Russell MA , et al. Randomized controlled trial of nasal nicotine spray in smoking cessation. Lancet 1992;340:324-329
CrossRef | Web of Science | Medline28
Perkins KA . Issues in the prevention of weight gain after smoking cessation. Ann Behav Med 1994;16:46-5229
Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1988.
30
Wise RA. Brain neuronal systems mediating reward processes. In: Smith JE, Lane JD, eds. Neurobiology of opiate reward mechanisms. New York: Elsevier Biomedical Press, 1983:405-38.
31
Di Chiara G ,Imperato A . Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 1988;85:5274-5278
CrossRef | Web of Science | Medline32
Pontieri FE ,Tanda G ,Orzi F ,Di Chiara G . Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996;382:255-257
CrossRef | Web of Science | Medline33
Clarke PB . Nicotine dependence -- mechanisms and therapeutic strategies. Biochem Soc Symp 1993;59:83-95
Web of Science | Medline34
Ascher JA ,Cole JO ,Colin JN , et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995;56:395-401
Web of Science | Medline35
Davidson J . Seizures and bupropion: a review. J Clin Psychiatry 1989;50:256-261
Web of Science | Medline36
Johnston JA ,Lineberry CG ,Ascher JA , et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 1991;52:450-456
Web of Science | Medline
- Citing Articles (391)
Citing Articles
1
Alberto de Hoyos, Carol Southard, Malcolm M. DeCamp. (2012) Perioperative Smoking Cessation. Thoracic Surgery Clinics 22:1, 1-12
CrossRef2
Amanda C Farley, Peter Hajek, Deborah Lycett, Paul Aveyard, Paul Aveyard. 2012. Interventions for preventing weight gain after smoking cessation. .
CrossRef3
Charles L. Pickens, Carlo Cifani, Brittany M. Navarre, Hila Eichenbaum, Florence R. Theberge, Michael H. Baumann, Donna J. Calu, Yavin Shaham. (2011) Effect of fenfluramine on reinstatement of food seeking in female and male rats: implications for the predictive validity of the reinstatement model. Psychopharmacology
CrossRef4
Richard D. Hurt, Jon O. Ebbert, J. Taylor Hays, David D. McFadden. (2011) Preventing Lung Cancer by Treating Tobacco Dependence. Clinics in Chest Medicine 32:4, 645-657
CrossRef5
Robert A. Schnoll, E. Paul Wileyto, Caryn Lerman. (2011) Extended Duration Therapy with Transdermal Nicotine may Attenuate Weight Gain Following Smoking Cessation. Addictive Behaviors
CrossRef6
Maher Karam-Hage, Stephen Strobbe, Jason D. Robinson, Kirk J. Brower. (2011) Bupropion-SR for Smoking Cessation in Early Recovery from Alcohol Dependence: A Placebo-Controlled, Double-Blind Pilot Study. The American Journal of Drug and Alcohol Abuse 37:6, 487-490
CrossRef7
L. David Hillis, Peter K. Smith, Jeffrey L. Anderson, John A. Bittl, Charles R. Bridges, John G. Byrne, Joaquin E. Cigarroa, Verdi J. DiSesa, Loren F. Hiratzka, Adolph M. Hutter, Michael E. Jessen, Ellen C. Keeley, Stephen J. Lahey, Richard A. Lange, Martin J. London, Michael J. Mack, Manesh R. Patel, John D. Puskas, Joseph F. Sabik, Ola Selnes, David M. Shahian, Jeffrey C. Trost, Michael D. Winniford. (2011) 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. Journal of the American College of Cardiology
CrossRef8
J. Taylor Hays, David D. McFadden, Jon O. Ebbert. (2011) Pharmacologic Agents for Tobacco Dependence Treatment: 2011 Update. Current Atherosclerosis Reports
CrossRef9
Harold S. Javitz, Gary E. Swan, Caryn Lerman. (2011) The dynamics of the urge-to-smoke following smoking cessation via pharmacotherapy. Addiction 106:10, 1835-1845
CrossRef10
A. Eden Evins, Gladys Pachas, David Mischoulon, Karen Urbanoski, Sara Carlini, Jessica Sousa, Kate Bentley, Nancy A. Rigotti, Johanna Nino-Gomez, Tsafrir Loebl, Amy C. Janes, Marc J. Kaufman, Maurizio Fava. (2011) A Double-Blind, Placebo-Controlled Trial of the NMDA Glycine Site Antagonist, GW468816, for Prevention of Relapse to Smoking in Females. Journal of Clinical Psychopharmacology 31:5, 597-602
CrossRef11
P. R. Killeen. (2011) Colloquium Paper: Markov model of smoking cessation. Proceedings of the National Academy of Sciences 108:Supplement_3, 15549-15556
CrossRef12
Kirsty Danielson, Penelope Truman, Bronwyn M Kivell. (2011) The effects of nicotine and cigarette smoke on the monoamine transporters. Synapse 65:9, 866-879
CrossRef13
Maria Caterina Grassi, Domenico Enea, Amy K. Ferketich, Bo Lu, Stefania Pasquariello, Paolo Nencini. (2011) Effectiveness of varenicline for smoking cessation: A 1-year follow-up study. Journal of Substance Abuse Treatment 41:1, 64-70
CrossRef14
Eric C. Donny, Anthony R. Caggiula, Matthew T. Weaver, Melissa E. Levin, Alan F. Sved. (2011) The reinforcement-enhancing effects of nicotine: Implications for the relationship between smoking, eating and weight. Physiology & Behavior 104:1, 143-148
CrossRef15
Shannon M. Clark, Ramzy Nakad. (2011) Pharmacotherapeutic Management of Nicotine Dependence in Pregnancy. Obstetrics and Gynecology Clinics of North America 38:2, 297-311
CrossRef16
S. L. Catz, L. M. Jack, J. B. McClure, H. S. Javitz, M. Deprey, S. M. Zbikowski, T. McAfee, J. Richards, G. E. Swan. (2011) Adherence to Varenicline in the COMPASS Smoking Cessation Intervention Trial. Nicotine & Tobacco Research 13:5, 361-368
CrossRef17
Robin Sperling, Kathryn G. Commons. (2011) Shifting topographic activation and 5-HT1A receptor-mediated inhibition of dorsal raphe serotonin neurons produced by nicotine exposure and withdrawal. European Journal of Neuroscience 33:10, 1866-1875
CrossRef18
Elizabeth V. Ratchford, James H. Black. (2011) Approach to Smoking Cessation in the Patient With Vascular Disease. Current Treatment Options in Cardiovascular Medicine 13:2, 91-102
CrossRef19
Carolyn M. Mazure, Benjamin Toll, Sherry A. McKee, Ran Wu, Stephanie S. O’Malley. (2011) Menstrual cycle phase at quit date and smoking abstinence at 6 weeks in an open label trial of bupropion. Drug and Alcohol Dependence 114:1, 68-72
CrossRef20
Hans-Ulrich Wittchen, Eva Hoch, Jens Klotsche, Stephan Muehlig. (2011) Smoking cessation in primary care - a randomized controlled trial of bupropione, nicotine replacements, CBT and a minimal intervention. International Journal of Methods in Psychiatric Research 20:1, 28-39
CrossRef21
Keita Inoue, Fuminao Takeshima, Koichiro Kadota, Aya Yoda, Yoichi Tatsuta, Yuki Nagaura, Sumako Yoshioka, Seiko Nakamichi, Kazuhiko Nakao, Yoshiyuki Ozono. (2011) Early Effects of Smoking Cessation and Weight Gain on Plasma Adiponectin Levels and Insulin Resistance. Internal Medicine 50:7, 707-712
CrossRef22
Edward D. Levin, Susan Slade, Corinne Wells, Margaret Pruitt, Vanessa Cousins, Marty Cauley, Ann Petro, Dawn Hampton, Jed Rose. (2011) Histamine H1 antagonist treatment with pyrilamine reduces nicotine self-administration in rats. European Journal of Pharmacology 650:1, 256-260
CrossRef23
Yann S. Mineur, Marina R. Picciotto. (2010) Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends in Pharmacological Sciences 31:12, 580-586
CrossRef24
Adrie W. Bruijnzeel, Mahendra Bishnoi, Irma A. Tuijl, Kim F. M. Keijzers, Kate R. Yavarovich, Tim M. Pasek, Jenna Ford, Jon C. Alexander, Hidetaka Yamada. (2010) Effects of prazosin, clonidine, and propranolol on the elevations in brain reward thresholds and somatic signs associated with nicotine withdrawal in rats. Psychopharmacology 212:4, 485-499
CrossRef25
David Gonzales, Douglas E. Jorenby, Thomas H. Brandon, Carmen Arteaga, Theodore C. Lee. (2010) Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo. Addiction 105:11, 2002-2013
CrossRef26
Mark A. Frye, Giulio Perugi. 2010. Comorbidity in Bipolar Disorder: A Focus on Addiction and Anxiety Disorders. , 31-43.
CrossRef27
Svetlana Semenova, Athina Markou. (2010) The α2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats. European Neuropsychopharmacology 20:10, 731-746
CrossRef28
Tam Spitzer Johnson. (2010) A brief review of pharmacotherapeutic treatment options in smoking cessation: bupropion versus varenicline. Journal of the American Academy of Nurse Practitioners 22:10, 557-563
CrossRef29
Arthur L. Brody, Edythe D. London, Richard E. Olmstead, Zoe Allen-Martinez, Stephanie Shulenberger, Matthew R. Costello, Anna L. Abrams, David Scheibal, Judah Farahi, Steven Shoptaw, Mark A. Mandelkern. (2010) Smoking-induced change in intrasynaptic dopamine concentration: Effect of treatment for Tobacco Dependence. Psychiatry Research: Neuroimaging 183:3, 218-224
CrossRef30
Lisa J. Merlo, Kimberly G. Blumenthal, Kendall Campbell, Morrow Omli, Mark S. Gold. 2010. Pharmacological Therapeutics for Relapse Reduction in Addictive Disorders. , 503-523.
CrossRef31
Firas H. Kobeissy, Carolina F. Braga, Noni A. Graham, Mark S. Gold. 2010. Pharmacological Therapeutics for Detoxification in Addictive Disorders. , 481-502.
CrossRef32
Sura Alwan, Jennita Reefhuis, Lorenzo D. Botto, Sonja A. Rasmussen, Adolfo Correa, Jan M. Friedman. (2010) Maternal use of bupropion and risk for congenital heart defects. American Journal of Obstetrics and Gynecology 203:1, 52.e1-52.e6
CrossRef33
Amit Sood, Jon O. Ebbert, Kavita Prasad, Ivana T. Croghan, Brent Bauer, Darrell R. Schroeder. (2010) A Randomized Clinical Trial of St. John's Wort for Smoking Cessation. The Journal of Alternative and Complementary Medicine 16:7, 761-767
CrossRef34
James H. Black. (2010) Evidence base and strategies for successful smoking cessation. Journal of Vascular Surgery 51:6, 1529-1537
CrossRef35
Austin G. Stack, Bhamidipati V.R. Murthy. (2010) Cigarette Use and Cardiovascular Risk in Chronic Kidney Disease: An Unappreciated Modifiable Lifestyle Risk Factor. Seminars in Dialysis 23:3, 298-305
CrossRef36
Jon O. Ebbert, J. Taylor Hays, Richard D. Hurt. (2010) Combination Pharmacotherapy for Stopping Smoking. Drugs 70:6, 643-650
CrossRef37
G. J. Madden, D. Kalman. (2010) Effects of bupropion on simulated demand for cigarettes and the subjective effects of smoking. Nicotine & Tobacco Research 12:4, 416-422
CrossRef38
Alice Egerton, John P. Shotbolt, Paul R.A. Stokes, Ella Hirani, Rabia Ahmad, Julia M. Lappin, Suzanne J. Reeves, Mitul A. Mehta, Oliver D. Howes, Paul M. Grasby. (2010) Acute effect of the anti-addiction drug bupropion on extracellular dopamine concentrations in the human striatum: An [11C]raclopride PET study. NeuroImage 50:1, 260-266
CrossRef39
Charles S. Wilcox, Nader Oskooilar, Janelle S. Erickson, Sonja K. Billes, Barbara B. Katz, Gary Tollefson, Eduardo Dunayevich. (2010) An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. Addictive Behaviors 35:3, 229-234
CrossRef40
Thomas J. Kiernan, Brian G. Hynes, Nicholas J. Ruggiero, Bryan P. Yan, Michael R. Jaff. (2010) Comprehensive Evaluation and Medical Management of Infrainguinal Peripheral Artery Disease: “When to Treat, When Not to Treat”. Techniques in Vascular and Interventional Radiology 13:1, 2-10
CrossRef41
Sarwar Hussain, Laurie Zawertailo, Usoa Busto, Martin Zack, Peter Farvolden, Peter Selby. (2010) The impact of chronic bupropion on plasma cotinine and on the subjective effects of ad lib smoking: A randomized controlled trial in unmotivated smokers. Addictive Behaviors 35:2, 164-167
CrossRef42
Mark J. Eisenberg, Lisa M. Blum, Kristian B. Filion, Stephane Rinfret, Louise Pilote, Gilles Paradis, Lawrence Joseph, André Gervais, Jennifer O’Loughlin. (2010) The efficacy of smoking cessation therapies in cardiac patients: A meta-analysis of randomized controlled trials. Canadian Journal of Cardiology 26:2, 73-79
CrossRef43
Allen Azizian, Liam J Nestor, Doris Payer, John R Monterosso, Arthur L Brody, Edythe D London. (2010) Smoking Reduces Conflict-Related Anterior Cingulate Activity in Abstinent Cigarette Smokers Performing a Stroop Task. Neuropsychopharmacology 35:3, 775-782
CrossRef44
B. A. Toll, S. Martino, A. Latimer, P. Salovey, S. O'Malley, S. Carlin-Menter, J. Hopkins, R. Wu, P. Celestino, K. M. Cummings. (2010) Randomized Trial: Quitline Specialist Training in Gain-Framed vs Standard-Care Messages for Smoking Cessation. JNCI Journal of the National Cancer Institute 102:2, 96-106
CrossRef45
T.R. Kosten, D.E. Davis. 2010. Comorbidity – Depression. , 308-316.
CrossRef46
M. J. Lewis, G. Balaji, H. Dixon, Y. Syed, K. E. Lewis. (2010) Influence of smoking abstinence and nicotine replacement therapy on heart rate and QT time-series. Clinical Physiology and Functional Imaging 30:1, 43-50
CrossRef47
Bianca Jupp, Andrew J. Lawrence. (2010) New horizons for therapeutics in drug and alcohol abuse. Pharmacology & Therapeutics 125:1, 138-168
CrossRef48
Matthew I. Palmatier, Melissa E. Levin, Kara L. Mays, Eric C. Donny, Anthony R. Caggiula, Alan F. Sved. (2009) Bupropion and nicotine enhance responding for nondrug reinforcers via dissociable pharmacological mechanisms in rats. Psychopharmacology 207:3, 381-390
CrossRef49
C. A. Oncken, H. R. Kranzler. (2009) What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy?. Nicotine & Tobacco Research 11:11, 1265-1273
CrossRef50
Maya J. Salameh, Elizabeth V. Ratchford. (2009) Update on Peripheral Arterial Disease and Claudication Rehabilitation. Physical Medicine and Rehabilitation Clinics of North America 20:4, 627-656
CrossRef51
Luíz Cláudio Martins, Sílvia Elaine Ferreira-Melo, Maricene Sabha, Otávio Rizzi Coelho, Juan Carlos Yugar-Toledo, Thiago Quinaglia, Marcos Mello Moreira, Antonio Coca, Heitor Moreno Júnior. (2009) Acute effects of pharmacotherapies in blood pressure in normotensive moderate smokers. Blood Pressure 18:5, 255-260
CrossRef52
Shannon Gravely-Witte, Donna E. Stewart, Neville Suskin, Sherry L. Grace. (2009) The association among depressive symptoms, smoking status and antidepressant use in cardiac outpatients. Journal of Behavioral Medicine 32:5, 478-490
CrossRef53
D. R. Strong, C. W. Kahler, A. M. Leventhal, A. M. Abrantes, E. Lloyd-Richardson, R. Niaura, R. A. Brown. (2009) Impact of bupropion and cognitive-behavioral treatment for depression on positive affect, negative affect, and urges to smoke during cessation treatment. Nicotine & Tobacco Research 11:10, 1142-1153
CrossRef54
Shoab A. Nazir, Marcia L. Erbland. (2009) Chronic Obstructive Pulmonary Disease. Drugs & Aging 26:10, 813-831
CrossRef55
Peter Gariti, Kevin Lynch, Arthur Alterman, Klye Kampman, Hu Xie, Kristi Varillo. (2009) Comparing smoking treatment programs for lighter smokers with and without a history of heavier smoking. Journal of Substance Abuse Treatment 37:3, 247-255
CrossRef56
Robert A. Schnoll, Freda Patterson. (2009) Sex heterogeneity in pharmacogenetic smoking cessation clinical trials. Drug and Alcohol Dependence 104, S94-S99
CrossRef57
M. C. Grassi, D. Enea, A. K. Ferketich, B. Lu, P. Nencini. (2009) A smoking ban in public places increases the efficacy of bupropion and counseling on cessation outcomes at 1 year. Nicotine & Tobacco Research 11:9, 1114-1121
CrossRef58
Fang Zheng, Matthew J. McConnell, Chang-Guo Zhan, Linda P. Dwoskin, Peter A. Crooks. (2009) QSAR study on maximal inhibition (Imax) of quaternary ammonium antagonists for S-(−)-nicotine-evoked dopamine release from dopaminergic nerve terminals in rat striatum. Bioorganic & Medicinal Chemistry 17:13, 4477-4485
CrossRef59
George F. Koob, G. Kenneth Lloyd, Barbara J. Mason. (2009) Development of pharmacotherapies for drug addiction: a Rosetta Stone approach. Nature Reviews Drug Discovery 8:6, 500-515
CrossRef60
Beatriz Roman. (2009) Patientsʼ Attitudes towards Generic Substitution of Oral Atypical Antipsychotics. CNS Drugs PAP,
CrossRef61
Shadi Nahvi, Nina A. Cooperman. (2009) Review: The Need for Smoking Cessation Among HIV-Positive Smokers. AIDS Education and Prevention 21:3_supplement, 14-27
CrossRef62
Yann S. Mineur, Marina R. Picciotto. (2009) Biological Basis for the Co-morbidity Between Smoking and Mood Disorders. Journal of Dual Diagnosis 5:2, 122-130
CrossRef63
Deirdre A. Glynn, John F. Cryan, Pauline Kent, Robert A. Flynn, Marcus P. Kennedy. (2009) Update on smoking cessation therapies. Advances in Therapy 26:4, 369-382
CrossRef64
Stuart G. Ferguson, Saul Shiffman. (2009) The relevance and treatment of cue-induced cravings in tobacco dependence. Journal of Substance Abuse Treatment 36:3, 235-243
CrossRef65
Amrinder S. Bhatti, Cigdem Aydin, Ozge Oztan, Zhiyuan Ma, Penny Hall, Rui Tao, Ceylan Isgor. (2009) Effects of a cannabinoid receptor (CB) 1 antagonist AM251 on behavioral sensitization to nicotine in a rat model of novelty-seeking behavior: correlation with hippocampal 5HT. Psychopharmacology 203:1, 23-32
CrossRef66
J. O. Ebbert, I. T. Croghan, A. Sood, D. R. Schroeder, J. T. Hays, R. D. Hurt. (2009) Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine & Tobacco Research 11:3, 234-239
CrossRef67
Kavita Mundey. (2009) An appraisal of smoking cessation aids. Current Opinion in Pulmonary Medicine 15:2, 105-112
CrossRef68
Nancy A. Rigotti, David Gonzales, Lowell C. Dale, Daniel Lawrence, Yuchiao Chang. (2009) A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain. Addiction 104:2, 266-276
CrossRef69
Amanda C Parsons, Mujahed Shraim, Jennie Inglis, Paul Aveyard, Peter Hajek, Amanda C Parsons. 2009. Interventions for preventing weight gain after smoking cessation. .
CrossRef70
Robert Swift, Lorenzo Leggio. 2009. Adjunctive Pharmacotherapy in the Treatment of Alcohol and Drug Dependence. , 287-310.
CrossRef71
Neil E. Paterson. (2009) Behavioural and pharmacological mechanisms of bupropion's anti-smoking effects: Recent preclinical and clinical insights. European Journal of Pharmacology 603:1-3, 1-11
CrossRef72
Michael A. Chandler, Stephen I. Rennard. 2009. Smoking Cessation. , 599-607.
CrossRef73
Peter Jatlow, Benjamin A. Toll, Vanessa Leary, Suchitra Krishnan-Sarin, Stephanie S. O’Malley. (2008) Comparison of expired carbon monoxide and plasma cotinine as markers of cigarette abstinence. Drug and Alcohol Dependence 98:3, 203-209
CrossRef74
Gerald Zernig, Reinhild Wallner, Ursula Grohs, Norbert Kriechbaum, Georg Kemmler, Alois Saria. (2008) A randomized trial of short psychotherapy versus sustained-release bupropion for smoking cessation. Addiction 103:12, 2024-2031
CrossRef75
V. I. Reus, B. J. Smith. (2008) Multimodal techniques for smoking cessation: a review of their efficacy and utilisation and clinical practice guidelines. International Journal of Clinical Practice 62:11, 1753-1768
CrossRef76
Piotr Tutka. (2008) Nicotinic receptor partial agonists as novel compounds for the treatment of smoking cessation. Expert Opinion on Investigational Drugs 17:10, 1473-1485
CrossRef77
José Carlos Titos-Arcos, Hacibe Hallal, Virginia Collados, Joaquín Plaza-Aniorte. (2008) Hepatitis aguda secundaria a bupropión. Gastroenterología y Hepatología 31:8, 549
CrossRef78
Andrea H. Weinberger, Jennifer C. Vessicchio, Kristi A. Sacco, Cerissa L. Creeden, K.N. Roy Chengappa, Tony P. George. (2008) A Preliminary Study of Sustained-Release Bupropion for Smoking Cessation in Bipolar Disorder. Journal of Clinical Psychopharmacology 28:5, 584-587
CrossRef79
Danielle E. McCarthy, Thomas M. Piasecki, Daniel L. Lawrence, Douglas E. Jorenby, Saul Shiffman, Timothy B. Baker. (2008) Psychological mediators of bupropion sustained-release treatment for smoking cessation. Addiction 103:9, 1521-1533
CrossRef80
Nicolas Rodondi, Pascal Bovet, Daniel Hayoz, Jacques Cornuz. (2008) The Impact of CAROtid plaque Screening on Smoking (CAROSS) cessation and control of other cardiovascular risk factors: Rationale and design of a randomized controlled trial. Contemporary Clinical Trials 29:5, 767-773
CrossRef81
Hao Wang, Daniel F. Heitjan. (2008) Modeling heaping in self‐reported cigarette counts. Statistics in Medicine 27:19, 3789-3804
CrossRef82
Kevin W. Johns, Jiri F. Frohlich, Gregory P. Bondy. (2008) Pharmacology of drugs used to treat smoking cessation and obesity. Canadian Journal of Cardiology 24, 22C-26C
CrossRef83
Jun'ichi Semba, Maki Wakuta. (2008) Chronic effect of nicotine on serotonin transporter mRNA in the raphe nucleus of rats: Reversal by co-administration of bupropion. Psychiatry and Clinical Neurosciences 62:4, 435-441
CrossRef84
D Bhattacharyya, SP Rai, LS Neog. (2008) Therapy for cessation of smoking. Medical Journal Armed Forces India 64:3, 254-259
CrossRef85
Ixchel Herrera-Guzmán, Esteve Gudayol-Ferré, Jennifer Lira-Mandujano, Jorge Herrera-Abarca, Daniel Herrera-Guzmán, Karina Montoya-Pérez, Joan Guardia-Olmos. (2008) Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder. Psychiatry Research 160:1, 72-82
CrossRef86
D. V. Conti, W. Lee, D. Li, J. Liu, D. Van Den Berg, P. D. Thomas, A. W. Bergen, G. E. Swan, R. F. Tyndale, N. L. Benowitz, C. Lerman, . (2008) Nicotinic acetylcholine receptor 2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Human Molecular Genetics 17:18, 2834-2848
CrossRef87
Reiji Yoshimura, Shingo Kakihara, Wakako Umene-Nakano, Atsuko Sugita, Hikaru Hori, Nobuhisa Ueda, Jun Nakamura. (2008) Acute risperidone treatment did not increase daily cigarette consumption or plasma levels of cotinine and caffeine: a pilot study. Human Psychopharmacology: Clinical and Experimental 23:4, 327-332
CrossRef88
Neil E. Paterson, Svetlana Semenova, Athina Markou. (2008) The effects of chronic versus acute desipramine on nicotine withdrawal and nicotine self-administration in the rat. Psychopharmacology 198:3, 351-362
CrossRef89
Tony P. George, Jennifer C. Vessicchio, Kristi A. Sacco, Andrea H. Weinberger, Melissa M. Dudas, Taryn M. Allen, Cerissa L. Creeden, Marc N. Potenza, Alan Feingold, Peter I. Jatlow. (2008) A Placebo-Controlled Trial of Bupropion Combined with Nicotine Patch for Smoking Cessation in Schizophrenia. Biological Psychiatry 63:11, 1092-1096
CrossRef90
Ziva D. Cooper, Margaret Haney. (2008) Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor. Addiction Biology 13:2, 188-195
CrossRef91
Spence M. Taylor, Corey A. Kalbaugh, Matthew G. Healy, Anna L. Cass, Bruce H. Gray, Eugene M. Langan, David L. Cull, Christopher G. Carsten, John W. York, Bruce A. Snyder, Jerry R. Youkey. (2008) Do Current Outcomes Justify More Liberal Use of Revascularization for Vasculogenic Claudication? A Single Center Experience of 1,000 Consecutively Treated Limbs. Journal of the American College of Surgeons 206:5, 1053-1062
CrossRef92
Su-Yan L Barrow. (2008) Is your knowledge up-to-date?. International Journal of Dental Hygiene 6:2, 150-151
CrossRef93
Gisela I. Robles, Devada Singh-Franco, Hoytin Lee Ghin. (2008) A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations. Clinical Therapeutics 30:5, 800-812
CrossRef94
Andrea T. Borchers, Carl. L. Keen, M. Eric Gershwin. (2008) Smoking Cessation: Significance and Implications for Children. Clinical Reviews in Allergy & Immunology 34:2, 231-249
CrossRef95
Curtis L. Cooper. (2008) Obstacles to Successful HCV Treatment in Substance Addicted Patients. Journal of Addictive Diseases 27:2, 61-68
CrossRef96
Wilbert S. Aronow. 2008. Management of Peripheral Arterial Disease in the Elderly. , 749-768.
CrossRef97
J.C. Virchow. (2008) Prävention von Erkrankungen des Respirationstrakts. Der Internist 49:2, 170-177
CrossRef98
Xiu Liu, Anthony R. Caggiula, Matthew I. Palmatier, Eric C. Donny, Alan F. Sved. (2008) Cue-induced reinstatement of nicotine-seeking behavior in rats: effect of bupropion, persistence over repeated tests, and its dependence on training dose. Psychopharmacology 196:3, 365-375
CrossRef99
Doug-Hyun Han, Keun-Ho Joe, Chul Na, Young-Sik Lee. (2008) Effect of genetic polymorphisms on smoking cessation: a trial of bupropion in Korean male smokers. Psychiatric Genetics 18:1, 11-16
CrossRef100
Benjamin A. Toll, Vanessa Leary, Ran Wu, Peter Salovey, Boris Meandzija, Stephanie S. O'Malley. (2008) A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain. Addictive Behaviors 33:1, 173-179
CrossRef101
Matthias E Liechti, Athina Markou. (2008) Role of the Glutamatergic System in Nicotine Dependence. CNS Drugs 22:9, 705-724
CrossRef102
Gary L Huber, Vijay K Mahajan. (2008) Successful Smoking Cessation. Disease Management & Health Outcomes 16:5, 335-343
CrossRef103
Rajesh R Patel, Jay H Ryu, Robert Vassallo. (2008) Cigarette Smoking and Diffuse Lung Disease. Drugs 68:11, 1511-1527
CrossRef104
Gary E Swan, Lisa M Jack, Harold S Javitz, Tim McAfee, Jennifer B McClure. (2008) Predictors of 12-Month Outcome in??Smokers Who Received Bupropion??Sustained-Release for??Smoking Cessation. CNS Drugs 22:3, 239-256
CrossRef105
Marie-Nöelle Beyens, Claire Guy, Genevieve Mounier, Sylvie Laporte, Michel Ollagnier. (2008) Serious Adverse Reactions of Bupropion for Smoking Cessation. Drug Safety 31:11, 1017-1026
CrossRef106
George S. Portugal, Thomas J. Gould. (2007) Bupropion dose-dependently reverses nicotine withdrawal deficits in contextual fear conditioning. Pharmacology Biochemistry and Behavior 88:2, 179-187
CrossRef107
Shoab A. Nazir, Mohammad M. Al-Hamed, Marcia L. Erbland. (2007) Chronic Obstructive Pulmonary Disease in the Older Patient. Clinics in Chest Medicine 28:4, 703-715
CrossRef108
Sheila A Doggrell. (2007) Which is the best primary medication for long-term smoking cessation – nicotine replacement therapy, bupropion or varenicline?. Expert Opinion on Pharmacotherapy 8:17, 2903-2915
CrossRef109
Isabel Nerín, Pilar Novella, Asunción Beamonte, Pilar Gargallo, Adriana Jiménez-Muro, Adriana Marqueta. (2007) Resultados del tratamiento del tabaquismo en una unidad especializada. Archivos de Bronconeumología 43:12, 669-673
CrossRef110
V. C. Wing, M. Shoaib. (2007) Examining the clinical efficacy of bupropion and nortriptyline as smoking cessation agents in a rodent model of nicotine withdrawal. Psychopharmacology 195:3, 303-313
CrossRef111
Ivan D. Montoya, Frank Vocci. (2007) Medications Development for the Treatment of Nicotine Dependence in Individuals with Schizophrenia. Journal of Dual Diagnosis 3:3-4, 113-150
CrossRef112
Teresa R Franklin, Ze wang, Jiongjiong Wang, Nathan Sciortino, Derek Harper, Yin Li, Ron Ehrman, Kyle Kampman, Charles P O'Brien, John A Detre, Anna Rose Childress. (2007) Limbic Activation to Cigarette Smoking Cues Independent of Nicotine Withdrawal: A Perfusion fMRI Study. Neuropsychopharmacology 32:11, 2301-2309
CrossRef113
Nicole M Stack. (2007) Smoking Cessation: An Overview of Treatment Options with a Focus on Varenicline. Pharmacotherapy 27:11, 1550-1557
CrossRef114
J. Cornuz. (2007) Smoking Cessation Interventions in Clinical Practice. European Journal of Vascular and Endovascular Surgery 34:4, 397-404
CrossRef115
Joseph C. Cappelleri, Andrew G. Bushmakin, Christine L. Baker, Elizabeth Merikle, Abayomi O. Olufade, David G. Gilbert. (2007) Multivariate framework of the Brief Questionnaire of Smoking Urges. Drug and Alcohol Dependence 90:2-3, 234-242
CrossRef116
Gerhard Rammes, Rainer Rupprecht. (2007) Modulation of Ligand-gated Ion Channels by Antidepressants and Antipsychotics. Molecular Neurobiology 35:2, 160-174
CrossRef117
Anna M. Lee, Christopher Jepson, Ewa Hoffmann, Leonard Epstein, Larry W. Hawk, Caryn Lerman, Rachel F. Tyndale. (2007) CYP2B6 Genotype Alters Abstinence Rates in a Bupropion Smoking Cessation Trial. Biological Psychiatry 62:6, 635-641
CrossRef118
Caryn Lerman, Mark G. LeSage, Kenneth A. Perkins, Stephanie S. O'Malley, Steven J. Siegel, Neal L. Benowitz, William A. Corrigall. (2007) Translational research in medication development for nicotine dependence. Nature Reviews Drug Discovery 6:9, 746-762
CrossRef119
Lowell C. Dale, Jon O. Ebbert, Elbert D. Glover, Ivana T. Croghan, Darrell R. Schroeder, Herbert H. Severson, Richard D. Hurt. (2007) Bupropion SR for the treatment of smokeless tobacco use. Drug and Alcohol Dependence 90:1, 56-63
CrossRef120
Kathleen M. Grant, Stephanie Sinclair Kelley, Lynette M. Smith, Sangeeta Agrawal, James R. Meyer, Debra J. Romberger. (2007) Bupropion and nicotine patch as smoking cessation aids in alcoholics. Alcohol 41:5, 381-391
CrossRef121
A. Eden Evins, Corinne Cather, Melissa A. Culhane, Alan Birnbaum, Jonathan Horowitz, Elaine Hsieh, Oliver Freudenreich, David C. Henderson, David A. Schoenfeld, Nancy A. Rigotti, Donald C. Goff. (2007) A 12-Week Double-Blind, Placebo-Controlled Study of Bupropion SR Added to High-Dose Dual Nicotine Replacement Therapy for Smoking Cessation or Reduction in Schizophrenia. Journal of Clinical Psychopharmacology 27:4, 380-386
CrossRef122
Nimish Sidhpura, Peter Redfern, Susan Wonnacott. (2007) Comparison of the effects of bupropion on nicotinic receptor-evoked [3H]dopamine release from rat striatal synaptosomes and slices. European Journal of Pharmacology 567:1-2, 102-109
CrossRef123
I. Mitrouska, I. Bouloukaki, N.M. Siafakas. (2007) Pharmacological approaches to smoking cessation. Pulmonary Pharmacology & Therapeutics 20:3, 220-232
CrossRef124
Masakazu Nakamura, Akira Oshima, Yoko Fujimoto, Nami Maruyama, Taro Ishibashi, Karen R. Reeves. (2007) Efficacy and tolerability of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clinical Therapeutics 29:6, 1040-1056
CrossRef125
Neil E. Paterson, David J. Balfour, Athina Markou. (2007) Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell. European Journal of Neuroscience 25:10, 3099-3108
CrossRef126
M K Ho, R F Tyndale. (2007) Overview of the pharmacogenomics of cigarette smoking. The Pharmacogenomics Journal 7:2, 81-98
CrossRef127
Anthony J. Alberg, Cindy L. Carter, Matthew J. Carpenter. (2007) Weight gain as an impediment to cigarette smoking cessation: A lingering problem in need of solutions. Preventive Medicine 44:4, 296-297
CrossRef128
Mary E. Becker, Michael A. Hertzberg, Scott D. Moore, Michelle F. Dennis, Deo S. Bukenya, Jean C. Beckham. (2007) A Placebo-Controlled Trial of Bupropion SR in the Treatment of Chronic Posttraumatic Stress Disorder. Journal of Clinical Psychopharmacology 27:2, 193-197
CrossRef129
Jon O. Ebbert, Amit Sood, J Taylor Hays, Lowell C. Dale, Richard D. Hurt. (2007) Treating Tobacco Dependence: Review of the Best and Latest Treatment Options. Journal of Thoracic Oncology 2:3, 249-256
CrossRef130
P Bredeloux, I Dubuc, J Costentin. (2007) Comparisons between bupropion and dexamphetamine in a range of in vivo tests exploring dopaminergic transmission. British Journal of Pharmacology 150:6, 711-719
CrossRef131
Neil E. Paterson, Athina Markou. (2007) Animal models and treatments for addiction and depression co-morbidity. Neurotoxicity Research 11:1, 1-32
CrossRef132
Anita H Clayton. (2007) Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity?. Expert Opinion on Pharmacotherapy 8:4, 457-466
CrossRef133
Eric C.K. Siu, Rachel F. Tyndale. (2007) Non-Nicotinic Therapies for Smoking Cessation. Annual Review of Pharmacology and Toxicology 47:1, 541-564
CrossRef134
William H. Frishman. (2007) Smoking Cessation Pharmacotherapy?Nicotine and Non-Nicotine Preparations. Preventive Cardiology 10:s2, 10-22
CrossRef135
Saadhna Panday, S. Priscilla Reddy, Robert A.C. Ruiter, Erik Bergström, Hein de Vries. (2007) Nicotine Dependence and Withdrawal Symptoms among Occasional Smokers. Journal of Adolescent Health 40:2, 144-150
CrossRef136
Ivana T. Croghan, Richard D. Hurt, Shaker R. Dakhil, Gary A. Croghan, Jeff A. Sloan, Paul J. Novotny, Kendrith M. Rowland, Albert Bernath, Mary L. Loots, Nguyet A. Le-Lindqwister, Loren K. Tschetter, Stewart C. Garneau, Kathleen A. Flynn, Larry P. Ebbert, Donald B. Wender, Charles L. Loprinzi. (2007) Randomized Comparison of a Nicotine Inhaler and Bupropion for Smoking Cessation and Relapse Prevention. Mayo Clinic Proceedings 82:2, 186-195
CrossRef137
I. T. Croghan, R. D. Hurt, S. R. Dakhil, G. A. Croghan, J. A. Sloan, P. J. Novotny, K. M. Rowland, A. Bernath, M. L. Loots, N. A. Le-Lindqwister, L. K. Tschetter, S. C. Garneau, K. A. Flynn, L. P. Ebbert, D. B. Wender, C. L. Loprinzi. (2007) Randomized Comparison of a Nicotine Inhaler and Bupropion for Smoking Cessation and Relapse Prevention. Mayo Clinic Proceedings 82:2, 186-195
CrossRef138
John R Hughes, Lindsay F Stead, Tim Lancaster, John R Hughes. 2007. Antidepressants for smoking cessation. .
CrossRef139
&NA;. (2007) Varenicline (Chantix) for Tobacco Dependence. Obstetrics & Gynecology 109:1, 192-193
CrossRef140
Wade H. Berrettini, E. Paul Wileyto, Leonard Epstein, Stephanie Restine, Larry Hawk, Peter Shields, Ray Niaura, Caryn Lerman. (2007) Catechol-O-Methyltransferase (COMT) Gene Variants Predict Response to Bupropion Therapy for Tobacco Dependence. Biological Psychiatry 61:1, 111-118
CrossRef141
Bernard Le Foll, Steven R Goldberg, Pierre Sokoloff. (2007) Dopamine D 3 receptor ligands for the treatment of tobacco dependence. Expert Opinion on Investigational Drugs 16:1, 45-57
CrossRef142
Kishore M Gadde, Glen L Xiong. (2007) Bupropion for weight reduction. Expert Review of Neurotherapeutics 7:1, 17-24
CrossRef143
David Olivier, Dan I. Lubman, Richard Fraser. (2007) Tobacco smoking within psychiatric inpatient settings: biopsychosocial perspective. Australian and New Zealand Journal of Psychiatry 41:7, 572-580
CrossRef144
Yves Martinet, Abraham Bohadana, Nathalie Wirth, Anna Spinosa. 2007. Proposer les traitements disponibles. Prescrire un traitement adapté. , 50-72.
CrossRef145
John C.M. Brust. 2007. Tabac. , 519-550.
CrossRef146
Sandra A. Brown, Suzette V. Glasner-Edwards, Susan R. Tate, John R. McQuaid, John Chalekian, Eric Granholm. (2006) Integrated Cognitive Behavioral Therapy Versus Twelve-Step Facilitation Therapy for Substance-Dependent Adults with Depressive Disorders. Journal of Psychoactive Drugs 38:4, 449-460
CrossRef147
James Shearer, Marian Shanahan. (2006) Cost effectiveness analysis of smoking cessation interventions. Australian and New Zealand Journal of Public Health 30:5, 428-434
CrossRef148
A. Palou Rotger, E. Sala Llinàs. (2006) Enfermedad pulmonar obstructiva crónica (2). Medicine - Programa de Formación Médica Continuada Acreditado 9:63, 4080-4087
CrossRef149
Linda P. Dwoskin, Anthony S. Rauhut, Kelley A. King-Pospisil, Michael T. Bardo. (2006) Review of the Pharmacology and Clinical Profile of Bupropion, an Antidepressant and Tobacco Use Cessation Agent. CNS Drug Reviews 12:3-4, 178-207
CrossRef150
Robert A Schnoll, Caryn Lerman. (2006) Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opinion on Emerging Drugs 11:3, 429-444
CrossRef151
S LAWVERE, M MAHONEY, K CUMMINGS, J KEPNER, A HYLAND, D LAWRENCE, J MURPHY. (2006) A Phase II study of St. John's Wort for smoking cessation
. Complementary Therapies in Medicine 14:3, 175-184
CrossRef152
Himanshu P. Upadhyaya. (2006) DO PATIENTS WITH ADHD HAVE A HARDER TIME QUITTING CIGARETTES?. Journal of the American Academy of Child & Adolescent Psychiatry 45:8, 891
CrossRef153
Marc E Mooney, Mehmet Sofuoglu. (2006) Bupropion for the treatment of nicotine withdrawal and craving. Expert Review of Neurotherapeutics 6:7, 965-981
CrossRef154
Fábio M. Haggsträm, José M. Chatkin, Eliana Sussenbach-Vaz, Débora H. Cesari, Claudia F. Fam, Carlos C. Fritscher. (2006) A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results. Pulmonary Pharmacology & Therapeutics 19:3, 205-209
CrossRef155
Fang Zheng, Ersin Bayram, Sangeetha P. Sumithran, Joshua T. Ayers, Chang-Guo Zhan, Jeffrey D. Schmitt, Linda P. Dwoskin, Peter A. Crooks. (2006) QSAR modeling of mono- and bis-quaternary ammonium salts that act as antagonists at neuronal nicotinic acetylcholine receptors mediating dopamine release. Bioorganic & Medicinal Chemistry 14:9, 3017-3037
CrossRef156
Oscar G Bukstein. (2006) Therapeutic challenges of attention-deficit hyperactivity disorder with substance use disorders. Expert Review of Neurotherapeutics 6:4, 541-549
CrossRef157
Jacques Cornuz. (2006) Treating tobacco use and dependence in clinical practice. Expert Opinion on Pharmacotherapy 7:6, 783-792
CrossRef158
Michael Kotlyar, Lisa H. Brauer, Mustafa al'Absi, David E. Adson, William Robiner, Paul Thuras, Jennifer Harris, Mary E. Finocchi, Carrie A. Bronars, Suzanne Candell, Dorothy K. Hatsukami. (2006) Effect of bupropion on physiological measures of stress in smokers during nicotine withdrawal. Pharmacology Biochemistry and Behavior 83:3, 370-379
CrossRef159
Thomas M. Piasecki. (2006) Relapse to smoking. Clinical Psychology Review 26:2, 196-215
CrossRef160
William H. Frishman, Walter Mitta, Adam Kupersmith, Tom Ky. (2006) Nicotine and Non-nicotine Smoking Cessation Pharmacotherapies. Cardiology in Review 14:2, 57-73
CrossRef161
Mark G. LeSage, Daniel E. Keyler, Paul R. Pentel. (2006) Current status of immunologic approaches to treating tobacco dependence: Vaccines and nicotine-specific antibodies. The AAPS Journal 8:1, E65-E75
CrossRef162
S. Cavuto, F. Bravi, M.C. Grassi, G. Apolone. (2006) Propensity score for the analysis of observational data: an introduction and an illustrative example. Drug Development Research 67:3, 208-216
CrossRef163
Maria Caterina Grassi, Domenico Enea, Rosanna Marchetti, Alessio Maria Caricati, Paolo Nencini. (2006) Combined counseling and bupropion therapy for smoking cessation: identification of outcome predictors. Drug Development Research 67:3, 271-279
CrossRef164
Eli V Gelfand, Christopher P Cannon. (2006) Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opinion on Investigational Drugs 15:3, 307-315
CrossRef165
Rohit Arora, James R. Sowers, Elijah Saunders, Jeffrey Probstfield, Harold L. Lazar. (2006) Cardioprotective Strategies to Improve Long-Term Outcomes Following Coronary Artery Bypass Surgery. Journal of Cardiac Surgery 21:2, 198-204
CrossRef166
Steven P. Marso, William R. Hiatt. (2006) Peripheral Arterial Disease in Patients With Diabetes. Journal of the American College of Cardiology 47:5, 921-929
CrossRef167
Bernard Foll, Steven R. Goldberg. (2006) Nicotine as a typical drug of abuse in experimental animals and humans. Psychopharmacology 184:3-4, 367-381
CrossRef168
David H. Malin, J. Ronald Lake, Tanya D. Smith, Habil N. Khambati, Rhonda L. Meyers-Paal, Ana L. Montellano, Ryan E. Jennings, Daniel S. Erwin, Stacey E. Presley, Barbara A. Perales. (2006) Bupropion attenuates nicotine abstinence syndrome in the rat. Psychopharmacology 184:3-4, 494-503
CrossRef169
Kenneth A. Perkins, Maxine Stitzer, Caryn Lerman. (2006) Medication screening for smoking cessation: a proposal for new methodologies. Psychopharmacology 184:3-4, 628-636
CrossRef170
Joel D. Killen, Stephen P. Fortmann, Greer M. Murphy, Chris Hayward, Christina Arredondo, DeAnn Cromp, Maria Celio, Laurie Abe, Yun Wang, Alan F. Schatzberg. (2006) Extended treatment with bupropion SR for cigarette smoking cessation.. Journal of Consulting and Clinical Psychology 74:2, 286-294
CrossRef171
Jaimee L. Heffner, Suzan Winders-Barrett, Robert M. Anthenelli. 2006. Obesity and Smoking. , 123-144.
CrossRef172
Wilbert S Aronow. (2006) Drug Treatment of Peripheral Arterial Disease in the Elderly. Drugs & Aging 23:1, 1-12
CrossRef173
David A. Tate. 2006. Abuso de sustancias y corazón. , 573-577.
CrossRef174
Anthony Rauhut, Linda Dwoskin, Michael Bardo. (2005) Tolerance does not develop to the decrease in nicotine self‐administration produced by repeated bupropion administration. Nicotine & Tobacco Research 7:6, 901-907
CrossRef175
Delwyn Catley, Kari Jo Harris, Kolawole Okuyemi, Matthew Mayo, Evan Pankey, Jasjit Ahluwalia. (2005) The influence of depressive symptoms on smoking cessation among African Americans in a randomized trial of bupropion. Nicotine & Tobacco Research 7:6, 859-870
CrossRef176
D OSLIN. (2005) Evidence-Based Treatment of Geriatric Substance Abuse. Psychiatric Clinics of North America 28:4, 897-911
CrossRef177
Vincenzo Teneggi, Stephen T. Tiffany, Lisa Squassante, Stefano Milleri, Luigi Ziviani, Alan Bye. (2005) Effect of sustained-release (SR) bupropion on craving and withdrawal in smokers deprived of cigarettes for 72 h. Psychopharmacology 183:1, 1-12
CrossRef178
Ramon Solhkhah, Timothy E. Wilens, Jeanine Daly, Jefferson B. Prince, Stephanie L. Van Patten, Joseph Biederman. (2005) Bupropion SR for the Treatment of Substance- Abusing Outpatient Adolescents with Attention- Deficit/Hyperactivity Disorder and Mood Disorders. Journal of Child and Adolescent Psychopharmacology 15:5, 777-786
CrossRef179
Sarah Ross, David Williams. (2005) Bupropion: risks and benefits. Expert Opinion on Drug Safety 4:6, 995-1003
CrossRef180
James W. Jefferson, James F. Pradko, Keith T. Muir. (2005) Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Clinical Therapeutics 27:11, 1685-1695
CrossRef181
Lois E. Krahn, Andrea DiMartini. (2005) Psychiatric and psychosocial aspects of liver transplantation. Liver Transplantation 11:10, 1157-1168
CrossRef182
T. Heitzer, T. Meinertz. (2005) Rauchen und koronare Herzkrankheit. Zeitschrift für Kardiologie 94:S3, iii30-iii42
CrossRef183
H. McRobbie, M. Lee, Z. Juniper. (2005) Non-nicotine pharmacotherapies for smoking cessation. Respiratory Medicine 99:10, 1203-1212
CrossRef184
Jon E. Grant, Marc N. Potenza. (2005) Tobacco Use and Pathological Gambling. Annals of Clinical Psychiatry 17:4, 237-241
CrossRef185
William White, David Crockford, Scott Patten, Nady el‐Guebaly. (2005) A randomized, open‐label pilot comparison of gabapentin and bupropion SR for smoking cessation. Nicotine & Tobacco Research 7:5, 809-813
CrossRef186
Charlotte Warner, Mohammed Shoaib. (2005) How does bupropion work as a smoking cessation aid?. Addiction Biology 10:3, 219-231
CrossRef187
Margaret Haney. (2005) The marijuana withdrawal syndrome: Diagnosis and treatment. Current Psychiatry Reports 7:5, 360-366
CrossRef188
T. R. Frieden, D. E. Blakeman. (2005) The Dirty Dozen: 12 Myths That Undermine Tobacco Control. American Journal of Public Health 95:9, 1500-1505
CrossRef189
Caryn Lerman, Christopher Jepson, E Paul Wileyto, Leonard H Epstein, Margaret Rukstalis, Freda Patterson, Vyga Kaufmann, Stephanie Restine, Larry Hawk, Ray Niaura, Wade Berrettini. (2005) Role of Functional Genetic Variation in the Dopamine D2 Receptor (DRD2) in Response to Bupropion and Nicotine Replacement Therapy for Tobacco Dependence: Results of Two Randomized Clinical Trials. Neuropsychopharmacology
CrossRef190
B. L. W. BENDERMACHER, E. M. WILLIGENDAEL, J. A. W. TEIJINK, M. H. PRINS. (2005) Medical management of peripheral arterial disease. Journal of Thrombosis and Haemostasis 3:8, 1628-1637
CrossRef191
Marc Mooney, David Babb, Joni Jensen, Dorothy Hatsukami. (2005) Interventions to increase use of nicotine gum: A randomized, controlled, single‐blind trial. Nicotine & Tobacco Research 7:4, 565-579
CrossRef192
Joseph Biederman, Stephen V Faraone. (2005) Attention-deficit hyperactivity disorder. The Lancet 366:9481, 237-248
CrossRef193
Jotham W. Coe, Michael G. Vetelino, Crystal G. Bashore, Michael C. Wirtz, Paige R. Brooks, Eric P. Arnold, Lorraine A. Lebel, Carol B. Fox, Steven B. Sands, Thomas I. Davis, David W. Schulz, Hans Rollema, F. David Tingley, Brian T. O’Neill. (2005) In pursuit of α4β2 nicotinic receptor partial agonists for smoking cessation: Carbon analogs of (−)-cytisine. Bioorganic & Medicinal Chemistry Letters 15:12, 2974-2979
CrossRef194
Joanne K. Singleton, Rona F. Levin, Harriet R. Feldman, Marie Truglio-Londrigan. (2005) Evidence for Smoking Cessation: Implications for Gender-Specific Strategies. Worldviews on Evidence-Based Nursing 2:2, 63-74
CrossRef195
Margaret Rukstalis, Christopher Jepson, Andrew Strasser, Kevin G. Lynch, Kenneth Perkins, Freda Patterson, Caryn Lerman. (2005) Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm. Psychopharmacology 180:1, 41-48
CrossRef196
Marta Torrens, Francina Fonseca, Gerard Mateu, Magí Farré. (2005) Efficacy of antidepressants in substance use disorders with and without comorbid depression. Drug and Alcohol Dependence 78:1, 1-22
CrossRef197
Joy M. Schmitz, Shelly L. Sayre, Angela L. Stotts, Jennifer Rothfleisch, Marc E. Mooney. (2005) Medication Compliance During a Smoking Cessation Clinical Trial: A Brief Intervention Using MEMS Feedback. Journal of Behavioral Medicine 28:2, 139-147
CrossRef198
F. Lebargy, L.-A. Becquart, B. Picavet. (2005) Épidémiologie du tabagisme. Aide à l’arrêt du tabac. EMC - Médecine 2:2, 171-190
CrossRef199
Timothy E. Wilens, Barbara R. Haight, Joseph P. Horrigan, James J. Hudziak, Norman E. Rosenthal, Daniel F. Connor, Kenneth D. Hampton, Nathalie E. Richard, Jack G. Modell. (2005) Bupropion XL in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled study. Biological Psychiatry 57:7, 793-801
CrossRef200
P. M. J. Puska, M. Barrueco, C. Roussos, A. Hider, S. Hogue. (2005) The participation of health professionals in a smoking-cessation programme positively influences the smoking cessation advice given to patients. International Journal of Clinical Practice 59:4, 447-452
CrossRef201
Olga D. Taraschenko, Vishal Panchal, Isabelle M. Maisonneuve, Stanley D. Glick. (2005) Is antagonism of α3β4 nicotinic receptors a strategy to reduce morphine dependence?. European Journal of Pharmacology 513:3, 207-218
CrossRef202
G. J. Johnson, J. Cosnes, J. C. Mansfield. (2005) Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Alimentary Pharmacology and Therapeutics 21:8, 921-931
CrossRef203
E. J. Wagena, P. Knipschild, M. P. A. Zeegers. (2005) Should nortriptyline be used as a first-line aid to help smokers quit? Results from a systematic review and meta-analysis. Addiction 100:3, 317-326
CrossRef204
Saman Warnakulasuriya, Gay Sutherland, Crispian Scully. (2005) Tobacco, oral cancer, and treatment of dependence. Oral Oncology 41:3, 244-260
CrossRef205
Robert West, Peter Hajek, Lindsay Stead, John Stapleton. (2005) Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 100:3, 299-303
CrossRef206
Mary T. Roth, Miranda R. Andrus, Eric C. Westman. (2005) Outcomes from an Outpatient Smoking-Cessation Clinic. Pharmacotherapy 25:2, 279-288
CrossRef207
Dipesh Joshi, Pattipati S. Naidu, Amanpreet Singh, Shrinivas K. Kulkarni. (2005) Reversal of Triazolam Tolerance and Withdrawal-Induced Hyperlocomotor Activity and Anxiety by Bupropion in Mice. Pharmacology 75:2, 93-97
CrossRef208
Paul M. Cinciripini, Janice Y. Tsoh, David W. Wetter, Cho Lam, Carl de Moor, Lynn Cinciripini, Walter Baile, Cheryl Anderson, John D. Minna. (2005) Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation.. Experimental and Clinical Psychopharmacology 13:4, 282-292
CrossRef209
Theodore V. Cooper, Robert C. Klesges, Margaret W. DeBon, Susan M. Zbikowski, Karen C. Johnson, Linda H. Clemens. (2005) A placebo controlled randomized trial of the effects of phenylpropanolamine and nicotine gum on cessation rates and postcessation weight gain in women. Addictive Behaviors 30:1, 61-75
CrossRef210
Kathleen T. Brady, Marcia L. Verduin. (2005) Pharmacotherapy of Comorbid Mood, Anxiety, and Substance Use Disorders. Substance Use & Misuse 40:13-14, 2021-2041
CrossRef211
Keigo Takagi, Nobuhide Kato, Syuichi Sasamoto, Yoshinobu Hata. (2005) Nicotine Replacement Therapy for Smoking Cessation. Nihon Kikan Shokudoka Gakkai Kaiho 56:5, 424-430
CrossRef212
M SOFUOGLU, T KOSTEN. (2004) Pharmacologic management of relapse prevention in addictive disorders. Psychiatric Clinics of North America 27:4, 627-648
CrossRef213
Helmut Niederhofer, Markus Huber. (2004) Bupropion May Support Psychosocial Treatment of Nicotine-Dependent Adolescents: Preliminary Results. Pharmacotherapy 24:11, 1524-1528
CrossRef214
Aung Htoo, Arunabh Talwar, Steven H. Feinsilver, Harly Greenberg. (2004) Smoking and sleep disorders. Medical Clinics of North America 88:6, 1575-1591
CrossRef215
Thomas R. Kosten, Therese A. Kosten. (2004) New medication strategies for comorbid substance use and bipolar affective disorders. Biological Psychiatry 56:10, 771-777
CrossRef216
Deborah Scharf, Saul Shiffman. (2004) Are there gender differences in smoking cessation, with and without bupropion? Pooled- and meta-analyses of clinical trials of Bupropion SR. Addiction 99:11, 1462-1469
CrossRef217
Andy McEwen, Robert West, Lesley Owen. (2004) GP prescribing of nicotine replacement and bupropion to aid smoking cessation in England and Wales. Addiction 99:11, 1470-1474
CrossRef218
Arunabh Talwar, Mukesh Jain, V.K. Vijayan. (2004) Pharmacotherapy of tobacco dependence. Medical Clinics of North America 88:6, 1517-1534
CrossRef219
JR Hughes, LF Stead, T Lancaster, John Hughes. 2004. Antidepressants for smoking cessation. .
CrossRef220
Harold S. Javitz, Gary E. Swan, Susan M. Zbikowski, Susan J. Curry, Timothy A. McAfee, Donna Decker, Richard Patterson, Lisa M. Jack. (2004) Return on Investment of Different Combinations of Bupropion SR Dose and Behavioral Treatment for Smoking Cessation in a Health Care Setting: An Employer's Perspective. Value in Health 7:5, 535-543
CrossRef221
H. J. Aubin, F. Lebargy, I. Berlin, C. Bidaut-Mazel, J. Chemali-Hudry, G. Lagrue. (2004) Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial. Addiction 99:9, 1206-1218
CrossRef222
Katherine A DeLaune, Joy M Schmitz. (2004) Treatment of Nicotine Addiction. Addictive Disorders & Their Treatment 3:3, 97-109
CrossRef223
Renato P Munhoz. (2004) Serotonin Syndrome Induced by a Combination of Bupropion and SSRIs. Clinical Neuropharmacology 27:5, 219-222
CrossRef224
Jos?? Mart??nez-Raga, Ana Sabater, Gaspar Cervera. (2004) Anorgasmia in a Patient Treated With Bupropion SR for Smoking Cessation. Journal of Clinical Psychopharmacology 24:4, 460-461
CrossRef225
Stephen I Rennard. (2004) Treatment of stable chronic obstructive pulmonary disease. The Lancet 364:9436, 791-802
CrossRef226
J Lee Westmaas, Thomas H Brandon. (2004) Reducing risk in smokers. Current Opinion in Pulmonary Medicine 10:4, 284-288
CrossRef227
José Miguel Chatkin, Carolina Mariante de Abreu, Fábio Maraschin Haggsträm, Mário Bernardes Wagner, Carlos Cezar Fritscher. (2004) Abstinence rates and predictors of outcome for smoking cessation: do Brazilian smokers need special strategies?. Addiction 99:6, 778-784
CrossRef228
C. Filozof, M. C. Fernandez Pinilla, A. Fernandez-Cruz. (2004) Smoking cessation and weight gain. Obesity Reviews 5:2, 95-103
CrossRef229
R. A. Schnoll, P. F. Engstrom. (2004) Tobacco Control in the Physician's Office: A Matter of Adequate Training and Resources. JNCI Journal of the National Cancer Institute 96:8, 573-575
CrossRef230
Arthur L. Brody, Mark A. Mandelkern, Grace Lee, Erlyn Smith, Mary Sadeghi, Sanjaya Saxena, Murray E. Jarvik, Edythe D. London. (2004) Attenuation of cue-induced cigarette craving and anterior cingulate cortex activation in bupropion-treated smokers: a preliminary study. Psychiatry Research: Neuroimaging 130:3, 269-281
CrossRef231
Bo S. Wong, John Fraser. (2004) The use of Bupropion for Smoking Cessation in Rural New South Wales. Australian Journal of Rural Health 12:2, 38-39
CrossRef232
Linda P Dwoskin, Sangeetha P Sumithran, Jun Zhu, A.Gabriela Deaciuc, Joshua T Ayers, Peter A Crooks. (2004) Subtype-selective nicotinic receptor antagonists: potential as tobacco use cessation agents. Bioorganic & Medicinal Chemistry Letters 14:8, 1863-1867
CrossRef233
Wallace B Pickworth, Eun M Lee, Mary E Abreu, Annie Umbricht, Kenzie L Preston. (2004) A laboratory study of hydromorphone and cyclazocine on smoking behavior in residential polydrug users. Pharmacology Biochemistry and Behavior 77:4, 711-715
CrossRef234
Kari Jo Harris, Kolawole S Okuyemi, Delwyn Catley, Matthew S Mayo, Bin Ge, Jasjit S Ahluwalia. (2004) Predictors of smoking cessation among African-Americans enrolled in a randomized controlled trial of bupropion. Preventive Medicine 38:4, 498-502
CrossRef235
Serena Tonstad, J Andrew Johnston. (2004) Does bupropion have advantages over other medical therapies in the cessation of smoking?. Expert Opinion on Pharmacotherapy 5:4, 727-734
CrossRef236
Debra J. Romberger, Kathleen Grant. (2004) Alcohol consumption and smoking status: the role of smoking cessation. Biomedicine & Pharmacotherapy 58:2, 77-83
CrossRef237
S. Holmes, N. Zwar, C.A. Jiménez-Ruiz, P.J. Ryan, D. Browning, L. Bergmann, J.A. Johnston. (2004) Bupropion as an aid to smoking cessation: a review of real-life effectiveness. International Journal of Clinical Practice 58:3, 285-291
CrossRef238
Belinda Borrelli, George Papandonatos, Bonnie Spring, Brian Hitsman, Raymond Niaura. (2004) Experimenter-defined quit dates for smoking cessation: adherence improves outcomes for women but not for men. Addiction 99:3, 378-385
CrossRef239
HIMANSHU P. UPADHYAYA, KATHLEEN T. BRADY, WEI WANG. (2004) Bupropion SR in Adolescents With Comorbid ADHD and Nicotine Dependence: A Pilot Study. Journal of the American Academy of Child & Adolescent Psychiatry 43:2, 199-205
CrossRef240
Gary E. Swan, Harold S. Javitz, Lisa M. Jack, Susan J. Curry, Tim McAfee. (2004) Heterogeneity in 12-month outcome among female and male smokers. Addiction 99:2, 237-250
CrossRef241
Georgia K. Johnson, Margaret Hill. (2004) Cigarette Smoking and the Periodontal Patient. Journal of Periodontology 75:2, 196-209
CrossRef242
Kay Wilhelm, Kay Wilhelm, Karen Arnold, Heather Niven, Robyn Richmond. (2004) Grey lungs and blue moods: smoking cessation in the context of lifetime depression history. Australian and New Zealand Journal of Psychiatry 38:11-12, 896-905
CrossRef243
Caryn Lerman, Ray Niaura, Bradley N. Collins, Paul Wileyto, Janet Audrain-McGovern, Angela Pinto, Larry Hawk, Leonard H. Epstein. (2004) Effect of Bupropion on Depression Symptoms in a Smoking Cessation Clinical Trial.. Psychology of Addictive Behaviors 18:4, 362-366
CrossRef244
Bonnie Spring, Neal Doran, Sherry Pagoto, Kristin Schneider, Regina Pingitore, Don Hedeker. (2004) Randomized Controlled Trial for Behavioral Smoking and Weight Control Treatment: Effect of Concurrent Versus Sequential Intervention.. Journal of Consulting and Clinical Psychology 72:5, 785-796
CrossRef245
Marie France Lan Cheong Wah, Lan Sem Hing Lan Cheong Wah. (2004) Generalized Seizure in a Mauritian Woman Taking Bupropion. PLoS Medicine 1:1, e15
CrossRef246
Judith J. Prochaska, Kevin Delucchi, Sharon M. Hall. (2004) A Meta-Analysis of Smoking Cessation Interventions With Individuals in Substance Abuse Treatment or Recovery.. Journal of Consulting and Clinical Psychology 72:6, 1144-1156
CrossRef247
Joel D. Killen, Thomas N. Robinson, Seth Ammerman, Chris Hayward, Jayna Rogers, Christi Stone, Deanne Samuels, Sara K. Levin, Sarah Green, Alan F. Schatzberg. (2004) Randomized Clinical Trial of the Efficacy of Bupropion Combined With Nicotine Patch in the Treatment of Adolescent Smokers.. Journal of Consulting and Clinical Psychology 72:4, 729-735
CrossRef248
Tony P George, Stephanie S O'Malley. (2004) Current pharmacological treatments for nicotine dependence. Trends in Pharmacological Sciences 25:1, 42-48
CrossRef249
Stephan Muehlig, Eva Hoch, Michael Hoefler, David Pittrow, Hans-Ulrich Wittchen. (2003) Aims, design and methods of the Smoking and Nicotine Dependence Awareness and Screening (SNICAS) study. International Journal of Methods in Psychiatric Research 12:4, 208-228
CrossRef250
Peter Hajek, Fiona Gillison, Hayden McRobbie. (2003) Stopping smoking can cause constipation. Addiction 98:11, 1563-1567
CrossRef251
Elbert D. Glover, Penny N. Glover, Thomas J. Payne. (2003) Treating Nicotine Dependence. The American Journal of the Medical Sciences 326:4, 183-186
CrossRef252
L. Susan Buttross, Joseph W. Kastner. (2003) A Brief Review of Adolescents and Tobacco: What We Know and Don???t Know. The American Journal of the Medical Sciences 326:4, 235-237
CrossRef253
Susan M Learned-Coughlin, Mats Bergström, Irina Savitcheva, John Ascher, Virginia D Schmith, Bengt Långstrom. (2003) In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biological Psychiatry 54:8, 800-805
CrossRef254
Adrie W. Bruijnzeel, Athina Markou. (2003) Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats. Synapse 50:1, 20-28
CrossRef255
Ashwin A. Patkar, Michael J. Vergare, Vikas Batra, Steven P. Weinstein, Frank T. Leone. (2003) Tobacco Smoking: Current Concepts in Etiology and Treatment. Psychiatry: Interpersonal and Biological Processes 66:3, 183-199
CrossRef256
P. Tonnesen, S. Tonstad, A. Hjalmarson, F. Lebargy, P. I. van Spiegel, A. Hider, R. Sweet, J. Townsend. (2003) A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. Journal of Internal Medicine 254:2, 184-192
CrossRef257
Lisa Sanderson Cox, Nicole L. Africano, Kenneth P. Tercyak, Kathryn L. Taylor. (2003) Nicotine dependence treatment for patients with cancer. Cancer 98:3, 632-644
CrossRef258
J. Taylor Hays, Jon O. Ebbert. (2003) Bupropion Sustained Release for Treatment of Tobacco Dependence. Mayo Clinic Proceedings 78:8, 1020-1024
CrossRef259
J. T. Hays, J. O. Ebbert. (2003) Bupropion Sustained Release for Treatment of Tobacco Dependence. Mayo Clinic Proceedings 78:8, 1020-1024
CrossRef260
Margaret Miller, Lisa Wood. (2003) Effectiveness of smoking cessation interventions: review of evidence and implications for best practice in Australian health care settings. Australian and New Zealand Journal of Public Health 27:3, 300-309
CrossRef261
Edward M. Sellers, Rachel F. Tyndale, Leona C. Fernandes. (2003) Decreasing smoking behaviour and risk through CYP2A6 inhibition. Drug Discovery Today 8:11, 487-493
CrossRef262
Lisa M Jack, Gary E Swan, Ella Thompson, Susan J Curry, Timothy McAfee, Sara Dacey, Katherine Bergman. (2003) Bupropion SR and smoking cessation in actual practice: methods for recruitment, screening, and exclusion for a field trial in a managed-care setting
CrossRef263
Sean M. Bagshaw, Bruce Cload, Janet Gilmour, Stephen T. Leung, Thomas J. Bowen. (2003) Drug-induced rash with eosinophilia and systemic symptoms syndrome with bupropion administration. Annals of Allergy, Asthma & Immunology 90:5, 572-575
CrossRef264
Gary E. Swan, Karen S. Hudmon, Taline V. Khroyan. 2003. Tobacco Dependence. .
CrossRef265
Robert West. (2003) Bupropion SR for smoking cessation. Expert Opinion on Pharmacotherapy 4:4, 533-540
CrossRef266
Bodo Cremers, Kathrin I. Schmidt, Christoph Maack, Hans-Joachim Schäfers, Michael Böhm. (2003) Catecholamine release in human heart by bupropion. European Journal of Pharmacology 467:1-3, 169-171
CrossRef267
Himanshu P. Upadhyaya, Kathleen T. Brady, Mollie Wharton, Jason Liao. (2003) Psychiatric Disorders and Cigarette Smoking Among Child and Adolescent Psychiatry Inpatients. The American Journal on Addictions 12:2, 144-152
CrossRef268
JOSÉ MARTÍNEZ-RAGA, FRANCIS KEANEY, GAY SUTHERLAND, BARTOLOME PEREZ-GALVEZ, JOHN STRANG. (2003) Treatment of nicotine dependence with bupropion SR: review of its efficacy, safety and pharmacological profile. Addiction Biology 8:1, 13-21
CrossRef269
Rohit Ahuja, Sandra B. Weibel, Frank T. Leone. (2003) Lung cancer: The oncologist's role in smoking cessation. Seminars in Oncology 30:1, 94-103
CrossRef270
Leslie Iversen, Richard A. Glennon. 2003. Antidepressants. .
CrossRef271
Tony P George, Jennifer C Vessicchio, Angelo Termine, Peter I Jatlow, Thomas R Kosten, Stephanie S O’Malley. (2003) A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biological Psychiatry 53:2, 136-143
CrossRef272
Thomas M. Piasecki, Douglas E. Jorenby, Stevens S. Smith, Michael C. Fiore, Timothy B. Baker. (2003) Smoking Withdrawal Dynamics: III. Correlates of Withdrawal Heterogeneity.. Experimental and Clinical Psychopharmacology 11:4, 276-285
CrossRef273
PATTI URSO. (2003) Match the best smoking cessation intervention to your patient. Clinical Nurse Specialist12-16,18-19,21
CrossRef274
J. Taylor Hays, Jon O. Ebbert. (2003) Bupropion for the Treatment of Tobacco Dependence. CNS Drugs 17:2, 71-83
CrossRef275
W Burleson Daviss, Raymond J Pan, James M Perel. (2003) Bupropion for attentiondeficit hyperactivity and comorbid disorders. Expert Review of Neurotherapeutics 3:1, 9-18
CrossRef276
Anne M Joseph, Steven S Fu. (2003) Smoking Cessation for Patients with Cardiovascular Disease. American Journal of Cardiovascular Drugs 3:5, 339-349
CrossRef277
Chin K Kim, Carsten M Schmalfuss, Richard S Schofield, David S Sheps. (2003) Pharmacological Treatment of Patients with Peripheral Arterial Disease. Drugs 63:7, 637-647
CrossRef278
Caryn Lerman, Peter G. Shields, E. Paul Wileyto, Janet Audrain, Larry H., Jr. Hawk, Angela Pinto, Susan Kucharski, Shiva Krishnan, Ray Niaura, Leonard H. Epstein. (2003) Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial.. Health Psychology 22:5, 541-548
CrossRef279
S. Fays, P. Trechot, J.L. Schmutz, J.F. Cuny, F. Truchetet, A. Barbaud. (2003) Bupropion and generalized acute urticaria: eight cases. British Journal of Dermatology 148:1, 177-178
CrossRef280
Edwin J Wagena, Maurice P A Zeegers, Constant P van Schayck, Emiel F M Wouters. (2003) Benefits and Risks of Pharmacological Smoking Cessation Therapies in Chronic Obstructive Pulmonary Disease. Drug Safety 26:6, 381-403
CrossRef281
PATTI URSO. (2003) Match the best smoking cessation intervention to your patient. The Nurse Practitioner 28:Supp: 2003, 12-16,18-19,21
CrossRef282
Richard D. Hurt. (2002) Pharmacotherapy for Alcoholic Smokers. Alcoholism: Clinical and Experimental Research 26:12, 1939-1941
CrossRef283
Joseph A Tracey. (2002) Zyban ® – is there a cause for concern?. Expert Opinion on Drug Safety 1:4, 303-305
CrossRef284
Caryn Lerman, Peter G Shields, E Paul Wileyto, Janet Audrain, Angela Pinto, Larry Hawk, Shiva Krishnan, Ray Niaura, Leonard Epstein. (2002) Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 12:8, 627-634
CrossRef285
R. S. Kahn, L. Certain, R. C. Whitaker. (2002) A Reexamination of Smoking Before, During, and After Pregnancy. American Journal of Public Health 92:11, 1801-1808
CrossRef286
Ivan Berlin, Henri-Jean Aubin, Anne-Marie Pedarriosse, Alexis Rames, , Sylvie Lancrenon, Gilbert Lagrue. (2002) Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation. Addiction 97:10, 1347-1354
CrossRef287
Tony P George, Jennifer C Vessicchio, Angelo Termine, Thomas A Bregartner, Alan Feingold, Bruce J Rounsaville, Thomas R Kosten. (2002) A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biological Psychiatry 52:1, 53-61
CrossRef288
Caryn Lerman, David Roth, Vyga Kaufmann, Janet Audrain, Larry Hawk, Aiyi Liu, Ray Niaura, Leonard Epstein. (2002) Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug and Alcohol Dependence 67:2, 219-223
CrossRef289
Richard D. Hurt, Troy D. Wolter, Nancy Rigotti, J.Taylor Hays, Raymond Niaura, Michael J. Durcan, David Gonzales, David P.L. Sachs, J.Andrew Johnston, Kenneth P. Offord. (2002) Bupropion for pharmacologic relapse prevention to smoking. Addictive Behaviors 27:4, 493-507
CrossRef290
N.H. Cox, P.M. Gordon, H. Dodd. (2002) Generalized pustular and erythrodermic psoriasis associated with bupropion treatment. British Journal of Dermatology 146:6, 1061-1063
CrossRef291
Richard Young, Richard A. Glennon. (2002) Nicotine and bupropion share a similar discriminative stimulus effect. European Journal of Pharmacology 443:1-3, 113-118
CrossRef292
Alan Cheng, Joel B. Braunstein, Cheryl Dennison, Caitlin Nass, Roger S. Blumenthal. (2002) Reducing global risk for cardiovascular disease: Using lifestyle changes and pharmacotherapy. Clinical Cardiology 25:5, 205-212
CrossRef293
Michael J. Durcan, Greg Deener, Jonathan White, J.Andrew Johnston, David Gonzales, Raymond Niaura, Nancy Rigotti, David P.L. Sachs. (2002) The effect of bupropion sustained-release on cigarette craving after smoking cessation. Clinical Therapeutics 24:4, 540-551
CrossRef294
Pallab Seth, Survjit Cheeta, Sonia Tucci, Sandra E. File. (2002) Nicotinic–serotonergic interactions in brain and behaviour. Pharmacology Biochemistry and Behavior 71:4, 795-805
CrossRef295
Sharon L. Collins. (2002) Current strategies for cessation of smoking for head and neck cancer patients. Current Opinion in Otolaryngology & Head and Neck Surgery 10:2, 69-79
CrossRef296
Richard D Hurt, Jon O Ebbert. (2002) Preventing lung cancer by stopping smoking. Clinics in Chest Medicine 23:1, 27-36
CrossRef297
Rigotti, Nancy A., . (2002) Treatment of Tobacco Use and Dependence. New England Journal of Medicine 346:7, 506-512
Full Text298
R. Donnelly, J.M.C. Yeung. (2002) Management of Intermittent Claudication: the Importance of Secondary Prevention. European Journal of Vascular and Endovascular Surgery 23:2, 100-107
CrossRef299
Andrew J. Johnston, John Ascher, Robert Leadbetter, Virginia D. Schmith, Dipak K. Patel, Michael Durcan, Beth Bentley. (2002) Pharmacokinetic Optimisation of Sustained-Release Bupropion for Smoking Cessation. Drugs 62:Supplement 2, 11-24
CrossRef300
Rod J. Rohrich, Dana M. Coberly, Jeffery K. Krueger, and Spencer A. Brown. (2002) Planning Elective Operations on Patients Who Smoke: Survey of North American Plastic Surgeons. Plastic and Reconstructive Surgery 109:1, 350-355
CrossRef301
Douglas Jorenby. (2002) Clinical Efficacy of Bupropion in the Management of Smoking Cessation. Drugs 62:Supplement 2, 25-35
CrossRef302
Raymond Niaura, David B. Abrams. (2002) Smoking cessation: Progress, priorities, and prospectus.. Journal of Consulting and Clinical Psychology 70:3, 494-509
CrossRef303
Henri-Jean Aubin. (2002) Tolerability and Safety of Sustained-Release Bupropion in the Management of Smoking Cessation. Drugs 62:Supplement 2, 45-52
CrossRef304
Gay Sutherland. (2002) Current Approaches to the Management of Smoking Cessation. Drugs 62:Supplement 2, 53-61
CrossRef305
David C. Henderson. (2002) Atypical Antipsychotic???Induced Diabetes Mellitus. CNS Drugs 16:2, 77-89
CrossRef306
Serena Tonstad. (2002) Use of Sustained-Release Bupropion in Specific Patient Populations for Smoking Cessation. Drugs 62:Supplement 2, 37-43
CrossRef307
Raymond Niaura, Bonnie Spring, Belinda Borrelli, Donald Hedeker, Michael G. Goldstein, Nancy Keuthen, Judy DePue, Jean Kristeller, Judy Ockene, Allan Prochazka, John A. Chiles, David B. Abrams. (2002) Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment.. Journal of Consulting and Clinical Psychology 70:4, 887-896
CrossRef308
Elaine C Johnstone, Emma E York, Robert T Walton. (2002) Genetic testing: the future of smoking cessation therapy?. Expert Review of Molecular Diagnostics 2:1, 60-68
CrossRef309
Richard D. Hurt. (2002) Pharmacotherapy for Alcoholic Smokers. Alcoholism: Clinical and Experimental Research 26:12, 1939
CrossRef310
James H. Stein, Magda Bushara, Khalaf Bushara, Patrick E. McBride, Douglas E. Jorenby, Michael C. Fiore. (2002) Smoking cessation, but not smoking reduction, reduces plasma homocysteine levels. Clinical Cardiology 25:1, 23-26
CrossRef311
Tomas Palomo, Trevor Archer, Richard J. Beninger, Richard M. Kostrzewa. (2002) Neurodevelopmental liabilities of substance abuse. Neurotoxicity Research 4:4, 267-279
CrossRef312
Athina Markou, Paul J. Kenny. (2002) Neuroadaptations to chronic exposure to drugs of abuse: Relevance to depressive symptomatology seen across psychiatric diagnostic categories. Neurotoxicity Research 4:4, 297-313
CrossRef313
Michael Kotlyar, Michael Golding, Dorothy K. Hatsukami, Brenda D. Jamerson. (2001) Effect of Nonnicotine Pharmacotherapy on Smoking Behavior. Pharmacotherapy 21:12, 1530-1548
CrossRef314
Jennifer O'Loughlin, Héla Makni, Michèle Tremblay, Chantal Lacroix, André Gervais, Véronique Déry, Garbis Meshefedjian, Gilles Paradis. (2001) Smoking Cessation Counseling Practices of General Practitioners in Montreal. Preventive Medicine 33:6, 627-638
CrossRef315
Jamie S. Ostroff, Natasha Buckshee, Carol A. Mancuso, David F. Yankelevitz, Claudia I. Henschke. (2001) Smoking Cessation Following CT Screening for Early Detection of Lung Cancer. Preventive Medicine 33:6, 613-621
CrossRef316
Catherine A. Fleming, Henri U. Balaguera, Donald E. Craven. (2001) RISK FACTORS FOR NOSOCOMIAL PNEUMONIA. Medical Clinics of North America 85:6, 1545-1563
CrossRef317
William H. Frishman, Tom Ky, Anjum Ismail. (2001) Tobacco Smoking, Nicotine, and Nicotine and Non-Nicotine Replacement Therapies. Heart Disease365-377
CrossRef318
IA Campbell. (2001) Safety profile of bupropion for chronic obstructive pulmonary disease. The Lancet 358:9286, 1010
CrossRef319
Jeffery K. Krueger, Rodney J. Rohrich. (2001) Clearing the Smoke: The Scientific Rationale for Tobacco Abstention with Plastic Surgery. Plastic and Reconstructive Surgery 108:4, 1063-1073
CrossRef320
Harri Vainio, Elisabete Weiderpass, Paul Kleihues. (2001) Smoking cessation in cancer prevention. Toxicology 166:1-2, 47-52
CrossRef321
T. Lancaster, L. Stead, S. Shepperd. (2001) Helping parents to stop smoking: which interventions are effective?. Paediatric Respiratory Reviews 2:3, 222-226
CrossRef322
Francisco García-Río, Soledad Serrano, Olga Mediano, Alberto Alonso, Jose Villamor. (2001) Safety profile of bupropion for chronic obstructive pulmonary disease. The Lancet 358:9286, 1009
CrossRef323
Anne M. Joseph, Lawrence C. An. (2001) Tobacco smoking in patients with cardiovascular disease. Current Treatment Options in Cardiovascular Medicine 3:4, 313-322
CrossRef324
Inder Mainie, Colm McGurk, Gavin McClintock, J Robinson. (2001) Seizures after buproprion overdose. The Lancet 357:9268, 1624
CrossRef325
Aimee L. McRae, Kathleen T. Brady, Susan C. Sonne. (2001) ALCOHOL AND SUBSTANCE ABUSE. Medical Clinics of North America 85:3, 779-801
CrossRef326
Mary T. Roth, Eric C. Westman. (2001) Use of Bupropion SR in a Pharmacist-Managed Outpatient Smoking-Cessation Program. Pharmacotherapy 21:5, 636-641
CrossRef327
DP Tashkin, R Kanner, W Bailey, S Buist, P Anderson, MA Nides, D Gonzales, G Dozier, MK Patel, BD Jamerson. (2001) Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. The Lancet 357:9268, 1571-1575
CrossRef328
B Jamerson. (2001) Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo. Clinical Therapeutics 23:5, 744-752
CrossRef329
I. Hindmarch. (2001) Expanding the horizons of depression: beyond the monoamine hypothesis. Human Psychopharmacology: Clinical and Experimental 16:3, 203-218
CrossRef330
&NA;. (2001) Non-nicotine pharmacotherapy may prove useful in smoking cessation. Drugs & Therapy Perspectives 17:5, 9-12
CrossRef331
Michael A. Hertzberg, Scott D. Moore, Michelle E. Feldman, Jean C. Beckham. (2001) A Preliminary Study of Bupropion Sustained-Release for Smoking Cessation in Patients With Chronic Posttraumatic Stress Disorder. Journal of Clinical Psychopharmacology 21:1, 94-98
CrossRef332
Brian Hitsman, Bonnie Spring, Belinda Borrelli, Raymond Niaura, George D. Papandonatos. (2001) Influence of antidepressant pharmacotherapy on behavioral treatment adherence and smoking cessation outcome in a combined treatment involving fluoxetine.. Experimental and Clinical Psychopharmacology 9:4, 355-362
CrossRef333
CHRISTOPHER J. WELSH, JOSEPH LIBERTO. (2001) The Use of Medication for Relapse Prevention in Substance Dependence Disorders. Journal of Psychiatric Practice 7:1, 15-31
CrossRef334
H. de Vries. 2001. Smoking Prevention and Smoking Cessation. , 14201-14205.
CrossRef335
Steven S. Smith, Douglas E. Jorenby, Michael C. Fiore, Jane E. Anderson, Michelle M. Mielke, Kirstin E. Beach, Thomas M. Piasecki, Timothy B. Baker. (2001) Strike while the iron is hot: Can stepped-care treatments resurrect relapsing smokers?. Journal of Consulting and Clinical Psychology 69:3, 429-439
CrossRef336
Kenneth A. Perkins. (2001) Smoking Cessation in Women. CNS Drugs 15:5, 391-411
CrossRef337
Kenneth A. Perkins, Marsha D. Marcus, Michele D. Levine, Delia D'Amico, Amy Miller, Michelle Broge, Jacquelyn Ashcom, Saul Shiffman. (2001) Cognitive-behavioral therapy to reduce weight concerns improves smoking cessation outcome in weight-concerned women.. Journal of Consulting and Clinical Psychology 69:4, 604-613
CrossRef338
Whooley, Mary A., Simon, Gregory E., . (2000) Managing Depression in Medical Outpatients. New England Journal of Medicine 343:26, 1942-1950
Full Text339
Gary T. Ferguson. (2000) Update on Pharmacologic Therapy for Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine 21:4, 723-738
CrossRef340
M N Pemberton, G J Atherton, M H Thornhill. (2000) Personal view: Violence and aggression at work. British Dental Journal 189:8, 409-410
CrossRef341
R S Levine. (2000) Smoking cessation: Briefing paper – Zyban. British Dental Journal 189:8, 412-412
CrossRef342
Karen Ahijevych, Ruth Yerardl, Nancy Nedilsky. (2000) Descriptive outcomes of the american lung association of ohio hypnotherapy smoking cessation program. International Journal of Clinical and Experimental Hypnosis 48:4, 374-387
CrossRef343
James C. McElnay, Terry A. Maguire, Ashlinn Drummond, Carmel M. Hughes. (2000) Smoking Cessation. Disease Management and Health Outcomes 8:3, 147-158
CrossRef344
P. Tønnesen. (2000) Treatment of nicotine dependency with bupropion. European Neuropsychopharmacology 10, 120-121
CrossRef345
Eoin McKinney, Robert Walton, Patricia Yudkin, Alice Fuller, Neil Haldar, David Mant, Mike Murphy, Ken Welsh, Sara Marshall. (2000) Pharmacogenetics 10:6, 483-491
CrossRef346
Nancy A. Rigotti, Julia H. Arnsten, Kathleen M. McKool, Kristen M. Wood-Reid, Richard C. Pasternak, Daniel E. Singer. (2000) Smoking by Patients in a Smoke-Free Hospital: Prevalence, Predictors, and Implications. Preventive Medicine 31:2, 159-166
CrossRef347
F López-Jiménez. (2000) Update in Internal Medicine. Archives of Medical Research 31:4, 329-352
CrossRef348
J. Taylor Hays. (2000) Tobacco Dependence Treatment in Patients With Heart and Lung Disease: Implications for Intervention and Review of Pharmacological Therapy. Journal of Cardiopulmonary Rehabilitation 20:4, 215-223
CrossRef349
Peter G. Shields. (2000) Epidemiology of tobacco carcinogenesis. Current Oncology Reports 2:3, 257-262
CrossRef350
ERIC T. MOOLCHAN, MONIQUE ERNST, JACK E. HENNINGFIELD. (2000) A Review of Tobacco Smoking in Adolescents: Treatment Implications. Journal of the American Academy of Child & Adolescent Psychiatry 39:6, 682-693
CrossRef351
Cynthia S Pomerleau, Ovide F Pomerleau, Rebecca J Namenek, Ann M Mehringer. (2000) Short-term weight gain in abstaining women smokers. Journal of Substance Abuse Treatment 18:4, 339-342
CrossRef352
Neal L. Benowitz, Margaret Wilson Peng. (2000) Non-Nicotine Pharmacotherapy for Smoking Cessation. CNS Drugs 13:4, 265-285
CrossRef353
Kristin J. Holm, Caroline M. Spencer. (2000) Bupropion. Drugs 59:4, 1007-1024
CrossRef354
Glen A. Lillington, Colm T. Leonard, David P.L. Sachs. (2000) SMOKING CESSATION. Clinics in Chest Medicine 21:1, 199-208
CrossRef355
Robert J. Hilsden, David C. Hodgins, Antje Timmer, Lloyd R. Sutherland. (2000) Clinical Reviews. Helping patients with Crohn's disease quit smoking. The American Journal of Gastroenterology 95:2, 352-358
CrossRef356
Rajendra H. Mehta, Eduardo Bossone, Kim A. Eagle. (2000) Current concepts in secondary prevention after acute myocardial infarction. Herz 25:1, 47-60
CrossRef357
Lirio S. Covey, Maria A. Sullivan, J. Andrew Johnston, Alexander H. Glassman, Mark D. Robinson, David P. Adams. (2000) Advances in Non-Nicotine Pharmacotherapy for Smoking Cessation. Drugs 59:1, 17-31
CrossRef358
Hazel M. Gilbert, David M. Warburton. (2000) Craving: A Problematic Concept in Smoking Research. Addiction Research & Theory 8:4, 381-397
CrossRef359
Joel D. Killen, Stephen P. Fortmann, Alan F. Schatzberg, Chris Hayward, Lisa Sussman, Micol Rothman, Laura Strausberg, Ann Varady. (2000) Nicotine patch and paroxetine for smoking cessation.. Journal of Consulting and Clinical Psychology 68:5, 883-889
CrossRef360
Trevor T Hansel, Maggie J Leckie, Shannon A Bryan, Peter J Barnes. (2000) Novel therapy for COPD. Expert Opinion on Investigational Drugs 9:1, 3-23
CrossRef361
Richard E. Wilcox, Carlton K. Erickson. (2000) Neurobiological Aspects of Addictions. Journal of Addictions Nursing 12:3-4, 117-132
CrossRef362
Michael G. Goldstein, Raymond Niaura. (2000) METHODS TO ENHANCE SMOKING CESSATION AFTER MYOCARDIAL INFARCTION. Medical Clinics of North America 84:1, 63-80
CrossRef363
Veljko J Djurić, Edward Dunn, David H Overstreet, Alina Dragomir, Meir Steiner. (1999) Antidepressant Effect of Ingested Nicotine in Female Rats of Flinders Resistant and Sensitive Lines. Physiology & Behavior 67:4, 533-537
CrossRef364
Kim A. Eagle, Robert A. Guyton, Ravin Davidoff, Gordon A. Ewy, James Fonger, Timothy J. Gardner, John Parker Gott, Howard C. Herrmann, Robert A. Marlow, William C. Nugent, Gerald T. O’Connor, Thomas A. Orszulak, Richard E. Rieselbach, William L. Winters, Salim Yusuf, Raymond J. Gibbons, Joseph S. Alpert, Kim A. Eagle, Timothy J. Gardner, Arthur Garson, Gabriel Gregoratos, Richard O. Russell, Sidney C. Smith. (1999) ACC/AHA guidelines for coronary artery bypass graft surgery. Journal of the American College of Cardiology 34:4, 1262-1347
CrossRef365
Thomas J Ryan, Elliott M Antman, Neil H Brooks, Robert M Califf, L.David Hillis, Loren F Hiratzka, Elliot Rapaport, Barbara Riegel, Richard O Russell, Earl E Smith, W.Douglas Weaver, Raymond J Gibbons, Joseph S Alpert, Kim A Eagle, Timothy J Gardner, Arthur Garson, Gabriel Gregoratos, Richard O Russell, Thomas J Ryan, Sidney C Smith. (1999) 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. Journal of the American College of Cardiology 34:3, 890-911
CrossRef366
Paul L. Ogburn, Richard D. Hurt, Ivana T. Croghan, Darrell R. Schroeder, Kirk D. Ramin, Kenneth P. Offord, Thomas P. Moyer. (1999) Nicotine patch use in pregnant smokers: Nicotine and cotinine levels and fetal effects. American Journal of Obstetrics and Gynecology 181:3, 736-743
CrossRef367
Beth Nordstrom, Taru Kinnunen, Christopher Utman, Arthur Garvey. (1999) Long-term effects of nicotine gum on weight gain after smoking cessation. Nicotine & Tobacco Research 1:3, 259-268
CrossRef368
Mike Franklin, Jingduan Chi, Cameron McGavin, Rena Hockney, Alison Reed, Gillian Campling, Richard W.R Whale, Phillip J Cowen. (1999) Neuroendocrine evidence for dopaminergic actions of hypericum extract (LI 160) in healthy volunteers. Biological Psychiatry 46:4, 581-584
CrossRef369
MICHAEL W. OWENS, BOAZ A. MARKEWITZ, D. KEITH PAYNE. (1999) Outpatient Management of Chronic Obstructive Pulmonary Disease. The American Journal of the Medical Sciences 318:2, 79
CrossRef370
Ellen R. Gritz, Chris Schacherer, Laura Koehly, Ingrid R. Nielsen, Elliot Abemayor. (1999) Smoking withdrawal and relapse in head and neck cancer patients. Head & Neck 21:5, 420-427
CrossRef371
H KRANZLER, H AMIN, V MODESTOLOWE, C ONCKEN. (1999) PHARMACOLOGIC TREATMENTS FOR DRUG AND ALCOHOL DEPENDENCE. Psychiatric Clinics of North America 22:2, 401-423
CrossRef372
Jonathan Foulds. (1999) The relationship between tobacco use and mental disorders. Current Opinion in Psychiatry 12:3, 303-306
CrossRef373
Lauri A. Laitinen, Kaj Koskela. (1999) Chronic bronchitis and chronic obstructive pulmonary disease: Finnish National Guidelines for Prevention and Treatment 1998–2007. Respiratory Medicine 93:5, 297-332
CrossRef374
Paula D Riggs, Susan K Mikulich, Elizabeth A Whitmore, Thomas J Crowley. (1999) Relationship of ADHD, depression, and non-tobacco substance use disorders to nicotine dependence in substance-dependent delinquents1Portions of this paper were presented at the annual meeting of the College of Problems on Drug Dependence (Nashville, TN, 1997).1. Drug and Alcohol Dependence 54:3, 195-205
CrossRef375
Anna M. Pou, Carl H. Snyderman. (1999) Strategies for curing tobacco addiction. Current Opinion in Otolaryngology & Head and Neck Surgery 7:2, 79
CrossRef376
Lirio S. Covey, Alexander H. Glassman, Fay Stetner. (1999) Naltrexone Effects on Short-Term and Long-Term Smoking Cessation. Journal of Addictive Diseases 18:1, 31-40
CrossRef377
Jorenby, Douglas E., Leischow, Scott J., Nides, Mitchell A., Rennard, Stephen I., Johnston, J. Andrew, Hughes, Arlene R., Smith, Stevens S., Muramoto, Myra L., Daughton, David M., Doan, Kimberli, Fiore, Michael C., Baker, Timothy B., . (1999) A Controlled Trial of Sustained-Release Bupropion, a Nicotine Patch, or Both for Smoking Cessation. New England Journal of Medicine 340:9, 685-691
Full Text378
Meldon Kahan. (1999) TREATMENT. Evidence-based Cardiovascular Medicine 3:1, 15-16
CrossRef379
Dorothy Hatsukami, Herbert Severson. (1999) Oral spit tobacco: addiction, prevention and treatment. Nicotine & Tobacco Research 1:1, 21-44
CrossRef380
Thomas E. Kottke. (1999) Practical steps to smoking cessation. Evidence-based Cardiovascular Medicine 3:1, 4-5
CrossRef381
Linda Sarna. (1999) Prevention: Tobacco control and cancer nursing. Cancer Nursing 22:1, 21-28
CrossRef382
Stephen L. Dewey, Jonathan D. Brodie, Madina Gerasimov, Bryan Horan, Eliot L. Gardner, Charles R. Ashby. (1999) A pharmacologic strategy for the treatment of nicotine addiction. Synapse 31:1, 76-86
CrossRef383
Anthony A. Floreani, Stephen I. Rennard. (1999) The role of cigarette smoke in the pathogenesis of asthma and as a trigger for acute symptoms. Current Opinion in Pulmonary Medicine 5:1, 38
CrossRef384
THOMAS R. KOSTEN, ATHINA MARKOU, GEORGE F. KOOB. (1998) Depression and Stimulant Dependence. The Journal of Nervous & Mental Disease 186:12, 737-745
CrossRef385
D. K. Taylor, K. R. Barber, B. A. McIntosh, M. Khan. (1998) The impact of post acute myocardial infarction (AMI) depression on patient compliance and risk factor modification. Psychology, Health & Medicine 3:4, 439-442
CrossRef386
Maria L. Terry, Henry D. Berkowitz, Morris D. Kerstein, FACS. (1998) TOBACCO. Surgical Clinics of North America 78:3, 409-429
CrossRef387
Jack E. Henningfield, Lakshmi Gopalan, Saul Shiffman. (1998) Tobacco dependence. Current Opinion in Psychiatry 11:3, 259-263
CrossRef388
(1998) Sustained-Release Bupropion for Smoking Cessation. New England Journal of Medicine 338:9, 619-620
Full Text389
(1998) The Evolving Pharmacotherapy of Smoking Cessation. Journal of General Internal Medicine 13:1, 55-57
CrossRef390
Benowitz, Neal L., . (1997) Treating Tobacco Addiction — Nicotine or No Nicotine?. New England Journal of Medicine 337:17, 1230-1231
Full Text391
John Britton, Alan Knox. (1997) No cures but some advances. The Lancet 350, SIII24
CrossRef
- Letters
